var title_f20_48_21248="Ommaya";
var content_f20_48_21248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The Ommaya reservoir",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    How the Ommaya reservoir works: To insert an Ommaya reservoir, the physician drills a burr hole and inserts the device's catheter through the patient's nondominant frontal lobe into the lateral ventricle. The reservoir, which has a self-sealing silicone injection dome, rests over the burr hole under a scalp flap. This creates a slight, soft bulge on the scalp about the size of a quarter. Usually, drugs are injected into the dome with a syringe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nursing Procedures, 4th Edition, Lippincott Williams &amp; Wilkins, Ambler 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21248=[""].join("\n");
var outline_f20_48_21248=null;
var title_f20_48_21249="Ligation uterine vsls 3";
var content_f20_48_21249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ligation of uterine vessels during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21249=[""].join("\n");
var outline_f20_48_21249=null;
var title_f20_48_21250="Approach elevated amylase";
var content_f20_48_21250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Approach to patients with an elevated serum amylase",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 621px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRCP: magnetic resonance cholangiopancreatography; ERCP: endoscopic retrograde cholangiopancreatography; EUS: endoscopic ultrasound.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21250=[""].join("\n");
var outline_f20_48_21250=null;
var title_f20_48_21251="Spina bifida D";
var content_f20_48_21251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spina bifida and hydrocephaly (Arnold-Chiari) at 33 postmenstrual weeks and one day",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oblique view showing the three horns of the lateral ventricles, which are dilated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21251=[""].join("\n");
var outline_f20_48_21251=null;
var title_f20_48_21252="Anatomy of lacrimal system";
var content_f20_48_21252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the lacrimal system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21252=[""].join("\n");
var outline_f20_48_21252=null;
var title_f20_48_21253="Altretamine: Drug information";
var content_f20_48_21253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Altretamine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/13/17620?source=see_link\">",
"    see \"Altretamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hexalen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hexalen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Ovarian cancer, persistent or recurrent:",
"     </b>",
"     Oral: 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in 4 divided doses for 14 or 21 days of a 28-day cycle",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F3280557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Temporarily withhold for 14 days or longer, and resume dose at 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for any of the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Platelet count &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     White blood cell count &lt;2000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or granulocyte count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Progressive neurotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal intolerance not responsive to antiemetic regimens",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Discontinue if neurotoxicity does not stabilize at 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hexalen&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F132331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer total daily dose orally as 4 divided doses after meals and at bedtime.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Palliative treatment of persistent or recurrent ovarian cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3149845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hexalen: Brand name altretamine [U.S., Canada, and Thailand], but also brand name for hexetidine [Greece]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (33%; severe 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (33%), leukopenia (5% to 15%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral sensory neuropathy (31%; mild: 9%; moderate-to-severe: 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased, serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, ataxia, depression, dizziness, hepatotoxicity, mood disorders, neurotoxicity, pruritus, rash, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F132334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to altretamine or any component of the formulation; pre-existing severe bone marrow suppression or severe neurologic toxicity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F132319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Peripheral blood counts should be done routinely before each cycle and during treatment;",
"     </b>",
"     dose-related bone marrow suppression is common. Use with caution in patients previously treated with other myelosuppressive agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Due to the potential for neurologic toxicity, neurologic examinations should be done routinely before each cycle and during treatment.",
"     </b>",
"     Peripheral neuropathy and neurotoxicity (ataxia, dizziness, vertigo, mood disorders, and disorders of consciousness) have been reported; usually occur in patients receiving continuous high-dose daily treatment and is generally reversible upon discontinuation. Has been administered safely to patients with pre-existing neuropathy (due to cisplatin); close monitoring is required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Concurrent use of altretamine and MAO inhibitors may cause severe orthostatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Altretamine may enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Altretamine. Management: Consider avoiding use of multivitamins that contain vitamin B6 in combination with altretamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May diminish the therapeutic effect of Altretamine. Specifically when altretamine is used in combination with Cisplatin the response duration may be diminished.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Altretamine may enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3280551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were noted in animal studies. There are no adequate and well-controlled studies in pregnant women. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant while on therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F132357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3280553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for toxicity in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F132336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after meals (and at bedtime).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5062377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hexalen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $1539.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3280558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (before each cycle and regularly during treatment), neurologic examination (before each cycle and regularly during treatment)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hexalen (AU, BG, GB, IL, JP, KP, NL, NO, NZ, RU, SE, TH);",
"     </li>",
"     <li>",
"      Hexastat (AR, FR, IT, PT);",
"     </li>",
"     <li>",
"      Hexinawas (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F132318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Altretamine structurally resembles alkylating agents, although has demonstrated activity in tumors resistant to classic alkylating agents. Cytotoxic effect not fully characterized, however it is theorized that metabolically activated oxidative N-demethylation intermediates bind to and damage DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F132333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributed into tissues high in lipid content and into tumor tissue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; rapid and extensive oxidative N-demethylation to active metabolites (pentamethylmelamine and tetramethylmelamine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~7 hours (range: 2-10 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 0.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%, &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alberts DS, Jiang C, Liu PY, et al, &ldquo;Long-Term Follow-Up of a Phase II Trial of Oral Altretamine for Consolidation of Clinical Complete Remission in Women With Stage III Epithelial Ovarian cancer in the Southwest Oncology Group,&rdquo; Int J Gynecol Cancer, 2004, 14(2):224-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Damia G and D'Incalci M, &ldquo;Clinical Pharmacokinetics of Altretamine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(6):439-48.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/48/21253/abstract-text/7656502/pubmed\" id=\"7656502\" target=\"_blank\">",
"        7656502",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keldsen N, Havsteen H, Vergote I, et al, &ldquo;Altretamine (Hexamethylmelamine) in the Treatment of Platinum-Resistant Ovarian Cancer: A Phase II Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2003, 88(2):118-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/48/21253/abstract-text/12586589/pubmed\" id=\"12586589\" target=\"_blank\">",
"        12586589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markman M, Blessing JA, Moore D, et al, &ldquo;Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 1998, 69(3):226-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/48/21253/abstract-text/9648592/pubmed\" id=\"9648592\" target=\"_blank\">",
"        9648592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8486 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21253=[""].join("\n");
var outline_f20_48_21253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708621\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132346\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132347\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132373\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132350\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132351\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671454\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671455\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3280557\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132328\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132315\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132331\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132329\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3149845\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132371\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132334\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132319\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298717\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132324\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132325\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3280551\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132357\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3280553\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132336\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5062377\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3280558\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132337\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132318\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132333\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/13/17620?source=related_link\">",
"      Altretamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_48_21254="Treatment and outcome of developmental dysplasia of the hip";
var content_f20_48_21254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and outcome of developmental dysplasia of the hip",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/48/21254/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/48/21254/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/48/21254/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/48/21254/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/48/21254/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/48/21254/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/48/21254/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/48/21254/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental dysplasia of the hip (DDH) describes a spectrum of conditions related to the development of the hip in infants and young children. The spectrum of conditions includes abnormalities of stability",
"    <span class=\"nowrap\">",
"     (dislocation/dislocatability",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     subluxation/subluxatability)",
"    </span>",
"    and abnormalities of shape of the femoral head and acetabulum (dysplasia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of DDH is initiated with referral to a pediatric orthopedic surgeon or other orthopedic surgeon who is familiar with the diagnosis and treatment of DDH. The treatment and outcome of typical DDH will be reviewed here. The epidemiology, pathogenesis, natural history, clinical features, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment are to obtain and maintain concentric reduction of the hip to provide an optimal environment for the development of the femoral head and acetabulum.",
"   </p>",
"   <p>",
"    The optimal environment requires that the cartilaginous surface of the femoral head be in contact with the cartilaginous floor of the acetabulum. The acetabulum has the capacity for growth and gradual resolution of dysplasia over time (months to years), if concentric reduction is maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of treatment are the same whether the child is diagnosed in the newborn nursery or later. However, the therapies necessary to achieve those goals vary depending upon age, stability, and severity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEWBORN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn nursery is a common place to discover hip instability or recognize risk factors for developmental dysplasia of the hip (DDH), especially breech positioning. Hip dislocation is rare in newborns, but mild laxity (instability) or a shallow acetabulum (dysplasia) are common findings [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/5\">",
"     5",
"    </a>",
"    ]. It is controversial whether these findings should be labeled as pathologic or as immaturity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of mild",
"    <span class=\"nowrap\">",
"     instability/laxity",
"    </span>",
"    is usually spontaneous improvement. Overdiagnosis and overtreatment of DDH in the newborn nursery should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/7\">",
"     7",
"    </a>",
"    ]. If mild laxity is found in the newborn nursery, repeat examination or referral to a pediatric orthopedist can be deferred until two weeks of age.",
"   </p>",
"   <p>",
"    Prompt referral to a pediatric orthopedist is indicated if the hip is dislocated or if laxity persists beyond two weeks of age. Laxity typically improves, and if so, ultrasonography should be performed at six weeks to assess for dysplasia. If the examination is normal, but risk factors for DDH are present, the American Academy of Pediatrics clinical practice guideline for early detection of DDH suggests ultrasonography after two weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Infants with risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     AGE LESS THAN SIX MONTHS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dislocation or instability",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Abduction splints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants younger than six months who have dislocated or persistently",
"    <span class=\"nowrap\">",
"     dislocatable/subluxatable",
"    </span>",
"    hips are usually treated with abduction splinting (eg, Pavlik harness, Aberdeen splint, von Rosen splint).",
"   </p>",
"   <p>",
"    The Pavlik harness is the most commonly used abduction splint [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/4\">",
"     4",
"    </a>",
"    ]. The Pavlik harness is a dynamic splint that prevents hip extension and adduction (which can lead to dislocation), but permits flexion and abduction. This positioning promotes stabilization of a dislocatable or subluxatable hip and usually leads to gradual reduction of a dislocated hip, even if it is not reducible on physical examination (",
"    <a class=\"graphic graphic_figure graphicRef66556 \" href=\"UTD.htm?26/58/27567\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Contraindications to the use of the Pavlik harness include muscle imbalance (spina bifida), severe stiffness (arthrogryposis), excessive laxity (Ehlers-Danlos syndrome), age older than 10 months, and a family situation in which consistent and careful use cannot be guaranteed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Pavlik harness is typically fit with hip flexion of 90&ordm; and limiting adduction to the midline. Weekly or biweekly adjustments are necessary to maintain the ideal position with the infant's rapid growth. Parents are cautioned regarding pressure in the groin area, which may cause femoral nerve palsy. Ultrasonography is used to monitor treatment.",
"   </p>",
"   <p>",
"    The duration of treatment varies depending upon age and severity, but two to three months is usually necessary. Treatment with the Pavlik harness should be discontinued after three weeks if a dislocated hip has not reduced; treatment should continue as described below for infants and children older than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Age 6 to 18 months with dislocation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment with a Pavlik harness is effective, but evidence from randomized trials is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/9\">",
"     9",
"    </a>",
"    ]. In observational studies, dislocatable or subluxatable hips improve in 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/4,10,11\">",
"     4,10,11",
"    </a>",
"    ]. The success rate for complete dislocation is approximately 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/11\">",
"     11",
"    </a>",
"    ], with success defined as achievement and maintenance of hip reduction. Early failure of the Pavlik harness treatment for developmental dysplasia of the hip (DDH) is more likely when there is low-percentage coverage (&lt;20 percent) of the femoral head and when there is irreducible dislocation on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Pavlik harness treatment is usually safe, potential complications include femoral nerve compression, brachial plexus palsy, knee subluxation, skin breakdown, residual acetabular dysplasia despite reduction, and osteonecrosis (avascular necrosis) of the femoral head [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/12\">",
"     12",
"    </a>",
"    ]. The most serious complication is osteonecrosis of the femoral head, which can result in permanent changes of the femoral head and acetabulum. The reported incidence of osteonecrosis varies widely; in most case series after 1995, the incidence is between 0 and 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Residual dysplasia is common, occurring in approximately 3 percent of treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/11\">",
"     11",
"    </a>",
"    ]. Follow-up radiographs are performed to monitor acetabular development, as described below. Most patients show gradual correction by age 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/1,2,4,11\">",
"     1,2,4,11",
"    </a>",
"    ]. If dysplasia persists past three to four years of age, surgical treatment is commonly recommended. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Long-term follow-up'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Double or triple diapering was recommended as a treatment for DDH in the past. However, this therapy is not effective and has the potential to be harmful since it may promote hip extension, an unfavorable position for normal hip development [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=see_link\">",
"     \"Epidemiology and pathogenesis of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Dysplasia without dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of infants with dysplasia without dislocation involves weighing the risks and benefits. Data supporting treatment over observation are limited. On the one hand, there is some evidence that dysplasia resolves over time without treatment, so few patients are likely to benefit from treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. On the other hand, treatment with abduction splinting has few risks, but a large potential benefit for the small number of patients in whom dysplasia would persist without treatment possibly requiring surgical intervention.",
"   </p>",
"   <p>",
"    Decisions regarding treatment are usually made by the orthopedic surgeon in conjunction with the child's parents after discussion of the risks and benefits of therapy. We suggest treatment with the Pavlik harness if isolated acetabular dysplasia (Graf Type IIa or worse) (",
"    <a class=\"graphic graphic_figure graphicRef56551 \" href=\"UTD.htm?15/33/15896\">",
"     figure 2",
"    </a>",
"    ) persists beyond six weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AGE 6 TO 18 MONTHS WITH DISLOCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed or open reduction performed in the operating room under anesthesia is usually necessary for children who are older than six months of age at the time of diagnosis or initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/4\">",
"     4",
"    </a>",
"    ]. The success rate for the Pavlik harness treatment in children in this age group is less than 50 percent, and there is a higher risk of osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Closed reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, an attempt is made at closed reduction under anesthesia. Some centers used home- or hospital-based skin traction to stretch out the soft tissue before the attempt at closed reduction. Hip arthrography and fluoroscopic imaging is performed intraoperatively to facilitate imaging and guide positioning.",
"   </p>",
"   <p>",
"    If the hip can be safely positioned, such that the femoral head is reduced into the acetabulum, a spica cast is applied to maintain the position. A percutaneous release of tight adductors may be performed to facilitate positioning. A computed tomography (CT) scan is often obtained immediately postoperatively, while contrast is still in the hip joint, to confirm positioning within the cast. Casting is continued for three to four months, usually with cast changes and repeat hip arthrography at six-week intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Open reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open reduction is recommended if the hip cannot be reduced and maintained with cast positioning. The timing for open reduction depends upon the center. Some centers defer open reduction until there is evidence of adequate hip maturity by the appearance of an ossific nucleus within the femoral head [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/20\">",
"     20",
"    </a>",
"    ]. The risk of osteonecrosis of the femoral head is lower when the ossific nucleus is present before open reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, when factoring in the benefit of early therapy, other centers proceed with open reduction whether or not the ossific nucleus is present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with closed reduction, the goal is to get the femoral head into the acetabulum and hold it with a spica cast. If closed reduction cannot be accomplished, an incision is made, and the hip capsule is opened to remove the obstacles to reduction that include the inverted labrum, the neolimbus, the pulvinar, the hypertrophied ligamentum teres and transverse acetabular ligament, and the tight iliopsoas tendon. After reduction, casting is continued for three to four months, usually with cast changes and repeat hip arthrography at six-week intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     AGE 18 MONTHS AND OLDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children 18 months and older, open reduction is usually needed. Depending on other factors, additional tendon releases, capsulorrhaphy, femoral shortening, and acetabular osteotomies also may be needed.",
"   </p>",
"   <p>",
"    Risks for long-term problems including stiffness, failure of treatment, residual dysplasia, and osteonecrosis are greater in older patients than in those who are treated earlier.",
"   </p>",
"   <p>",
"    In making treatment decisions, the risks of treatment are weighed against the untreated natural history. In general, reduction of a unilateral dislocation is recommended until 10 to 12 years of age. Bilateral dislocations after age eight years are sometimes left untreated, since results of treatment are likely to be less satisfactory than the untreated natural history [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link&amp;anchor=H119602133#H119602133\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LONG-TERM FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency and duration of long-term follow-up depends upon the treating orthopedic surgeon. As a general rule, children treated for hip dysplasia should have annual radiographs until they are at least six years old to look for late complications, such as osteonecrosis and to ensure that the hip is developing normally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of treated developmental dysplasia of the hip (DDH) depends upon the age of diagnosis, the severity, and the success of treatment. The natural history of untreated DDH serves as a baseline for comparison. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link&amp;anchor=H119602133#H119602133\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most neonatal hips with instability or mild dysplasia resolve spontaneously. When DDH is diagnosed in a newborn who has instability on examination or dysplasia on ultrasonography, treatment with abduction splinting is successful in the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/11,25\">",
"     11,25",
"    </a>",
"    ]. Long-term follow-up is important to monitor residual dysplasia.",
"   </p>",
"   <p>",
"    Residual dysplasia, either following treatment or undiagnosed, may result in progression to premature degenerative joint disease. A population-based study of 2.2 million children (1967 to 2004) found a 2.6-fold increase (95% CI 1.4-4.8) in total hip replacements in young adults who had been diagnosed with neonatal hip instability compared with those without neonatal hip instability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21254/abstract/26\">",
"     26",
"    </a>",
"    ]. The majority of young adults who underwent hip replacement that was attributed to dysplasia were not known to have neonatal hip instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=see_link\">",
"       \"Patient information: Developmental dysplasia of the hip (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of treatment of developmental dysplasia of the hip (DDH) are to obtain and maintain concentric reduction of the hip to provide an optimal environment for the development of the femoral head and acetabulum. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with abduction splinting for infants aged zero to six months of age with hip dislocation or instability (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dislocation or instability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest abduction splinting for infants who have acetabular dysplasia without dislocation (Graf Type IIa or worse) (",
"      <a class=\"graphic graphic_figure graphicRef56551 \" href=\"UTD.htm?15/33/15896\">",
"       figure 2",
"      </a>",
"      ) that persists beyond six weeks of age (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Dysplasia without dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Closed or open reduction is usually necessary for children who are older than six months of age at the time of diagnosis or initiation of therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Age 6 to 18 months with dislocation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Age 18 months and older'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who have been treated for DDH should be monitored for osteonecrosis and other complications until they are at least six years old. The frequency and duration of long-term follow-up depends upon the treating orthopedic surgeon. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The long-term outcome of treated DDH depends upon the age of diagnosis, the severity, and the success of treatment. Treatment with abduction splinting achieves and maintains hip reduction in the vast majority of infants with DDH who are treated during the first six months of life. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18948716\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Nicholas A Waanders, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/1\">",
"      Harris NH, Lloyd-Roberts GC, Gallien R. Acetabular development in congenital dislocation of the hip. With special reference to the indications for acetabuloplasty and pelvic or femoral realignment osteotomy. J Bone Joint Surg Br 1975; 57:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/2\">",
"      Lindstrom JR, Ponseti IV, Wenger DR. Acetabular development after reduction in congenital dislocation of the hip. J Bone Joint Surg Am 1979; 61:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/3\">",
"      Novacheck TF. Developmental dysplasia of the hip. Pediatr Clin North Am 1996; 43:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/4\">",
"      Weinstein SL, Mubarak SJ, Wenger DR. Developmental hip dysplasia and dislocation: Part II. Instr Course Lect 2004; 53:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/5\">",
"      Bialik V, Bialik GM, Blazer S, et al. Developmental dysplasia of the hip: a new approach to incidence. Pediatrics 1999; 103:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/6\">",
"      Harcke HT. Developmental dysplasia of the hip: a spectrum of abnormality. Pediatrics 1999; 103:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/7\">",
"      US Preventive Services Task Force. Screening for developmental dysplasia of the hip: recommendation statement. Pediatrics 2006; 117:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/8\">",
"      Clinical practice guideline: early detection of developmental dysplasia of the hip. Committee on Quality Improvement, Subcommittee on Developmental Dysplasia of the Hip. American Academy of Pediatrics. Pediatrics 2000; 105:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/9\">",
"      Dezateux C, Rosendahl K. Developmental dysplasia of the hip. Lancet 2007; 369:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/10\">",
"      Kalamchi A, MacFarlane R 3rd. The Pavlik harness: results in patients over three months of age. J Pediatr Orthop 1982; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/11\">",
"      Cashman JP, Round J, Taylor G, Clarke NM. The natural history of developmental dysplasia of the hip after early supervised treatment in the Pavlik harness. A prospective, longitudinal follow-up. J Bone Joint Surg Br 2002; 84:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/12\">",
"      Mubarak S, Garfin S, Vance R, et al. Pitfalls in the use of the Pavlik harness for treatment of congenital dysplasia, subluxation, and dislocation of the hip. J Bone Joint Surg Am 1981; 63:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/13\">",
"      Almby B, Hjelmstedt A, L&ouml;nnerholm T. Neonatal hip instability. Reason for failure of early abduction treatment. Acta Orthop Scand 1979; 50:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/14\">",
"      Lerman JA, Emans JB, Millis MB, et al. Early failure of Pavlik harness treatment for developmental hip dysplasia: clinical and ultrasound predictors. J Pediatr Orthop 2001; 21:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/15\">",
"      Suzuki S, Kashiwagi N, Kasahara Y, et al. Avascular necrosis and the Pavlik harness. The incidence of avascular necrosis in three types of congenital dislocation of the hip as classified by ultrasound. J Bone Joint Surg Br 1996; 78:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/16\">",
"      Wood MK, Conboy V, Benson MK. Does early treatment by abduction splintage improve the development of dysplastic but stable neonatal hips? J Pediatr Orthop 2000; 20:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/17\">",
"      Sucato DJ, Johnston CE 2nd, Birch JG, et al. Outcome of ultrasonographic hip abnormalities in clinically stable hips. J Pediatr Orthop 1999; 19:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/18\">",
"      Eidelman M, Katzman A, Freiman S, et al. Treatment of true developmental dysplasia of the hip using Pavlik's method. J Pediatr Orthop B 2003; 12:253.",
"     </a>",
"    </li>",
"    <li>",
"     Weinstein SL. Developmental hip dysplasia and dislocation. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, 2006. p.988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/20\">",
"      Clarke NM, Jowett AJ, Parker L. The surgical treatment of established congenital dislocation of the hip: results of surgery after planned delayed intervention following the appearance of the capital femoral ossific nucleus. J Pediatr Orthop 2005; 25:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/21\">",
"      Carney BT, Clark D, Minter CL. Is the absence of the ossific nucleus prognostic for avascular necrosis after closed reduction of developmental dysplasia of the hip? J Surg Orthop Adv 2004; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/22\">",
"      Segal LS, Boal DK, Borthwick L, et al. Avascular necrosis after treatment of DDH: the protective influence of the ossific nucleus. J Pediatr Orthop 1999; 19:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/23\">",
"      Luhmann SJ, Schoenecker PL, Anderson AM, Bassett GS. The prognostic importance of the ossific nucleus in the treatment of congenital dysplasia of the hip. J Bone Joint Surg Am 1998; 80:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/24\">",
"      Crawford AH, Mehlman CT, Slovek RW. The fate of untreated developmental dislocation of the hip: long-term follow-up of eleven patients. J Pediatr Orthop 1999; 19:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/25\">",
"      Nakamura J, Kamegaya M, Saisu T, et al. Treatment for developmental dysplasia of the hip using the Pavlik harness: long-term results. J Bone Joint Surg Br 2007; 89:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21254/abstract/26\">",
"      Engesaeter I&Oslash;, Lie SA, Lehmann TG, et al. Neonatal hip instability and risk of total hip replacement in young adulthood: follow-up of 2,218,596 newborns from the Medical Birth Registry of Norway in the Norwegian Arthroplasty Register. Acta Orthop 2008; 79:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6293 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21254=[""].join("\n");
var outline_f20_48_21254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEWBORN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AGE LESS THAN SIX MONTHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dislocation or instability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Abduction splints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Dysplasia without dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AGE 6 TO 18 MONTHS WITH DISLOCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Closed reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Open reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AGE 18 MONTHS AND OLDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LONG-TERM FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18948716\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6293|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/58/27567\" title=\"figure 1\">",
"      Pavlik harness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/33/15896\" title=\"figure 2\">",
"      Graf hip types",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=related_link\">",
"      Clinical features and diagnosis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/199?source=related_link\">",
"      Epidemiology and pathogenesis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=related_link\">",
"      Patient information: Developmental dysplasia of the hip (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_48_21255="Prurigo nodularis 1";
var content_f20_48_21255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53475%7EDERM%2F66268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53475%7EDERM%2F66268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Discrete, excoriated nolules on the leg of a patient with nodular prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple nodules, some of which excoriated, on the lower limb of a patient with nodular prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21255=[""].join("\n");
var outline_f20_48_21255=null;
var title_f20_48_21256="Left-sided heart failure - high power";
var content_f20_48_21256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver biospy from a patient with left-sided heart failure (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hepatocytes have been lost from liver plates and replaced by red blood cells. This finding has been called \"defecation of red blood cells into the space of Disse\" by earlier pathologists, who described this lesion in patients with chronic Budd-Chiari syndrome. Note that the sinusoids are not dilated as is seen in right-sided heart failure. Hypoxemia is the cause of hepatocyte necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21256=[""].join("\n");
var outline_f20_48_21256=null;
var title_f20_48_21257="Upper airway size during tidal breathing";
var content_f20_48_21257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Upper airway size during tidal breathing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dynamic changes in cross-sectional area at midtonsillar level (level 2) during tidal breathing of control subjects (top panels); and in subjects with obstructive sleep apnea&nbsp;(bottom panels), with 5-vol increments of inspiration (Ins) and 5-vol increments of expiration (Exp). Note the differences in anteroposterior (A-P) and lateral airway dimension.",
"    <div class=\"footnotes\">",
"     %: percent; Ins: inspiration; Exp: expiration.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Arens R, Sin S, McDonough J, et al. Changes in upper airway size during tidal breathing in children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2005; 171:1298. Official Journal of the American Thoracic Society. Copyright &copy; 2005 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21257=[""].join("\n");
var outline_f20_48_21257=null;
var title_f20_48_21258="Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults";
var content_f20_48_21258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/48/21258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/48/21258/contributors\">",
"     Franklin D Lowy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/48/21258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/48/21258/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/48/21258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/48/21258/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/48/21258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methicillin resistance in S. aureus is defined as an oxacillin minimum inhibitory concentration (MIC) &ge;4",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Isolates resistant to oxacillin or methicillin are also resistant to other beta-lactam agents, including oxacillin, dicloxacillin, and cefazolin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vancomycin largely remains the antibiotic of choice for the treatment of invasive methicillin-resistant S. aureus (MRSA) infections; alternative agents should be considered in the setting of adverse effects to vancomycin or infection with a pathogen with inadequate susceptibility to vancomycin.",
"   </p>",
"   <p>",
"    The approach to treatment of invasive MRSA infections in adults will be reviewed here. Issues related to the treatment of MRSA skin and soft tissue infections, the mechanisms of antibiotic resistance, epidemiology, detection, and prevention and control of MRSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to management of patients with MRSA isolates with increased vancomycin MICs are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=see_link\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PARENTERAL AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vancomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vancomycin is a glycopeptide that inhibits cell wall synthesis. It remains an important antibiotic for the treatment of invasive methicillin-resistant S. aureus (MRSA) infections, despite increasing concern about &ldquo;MIC creep&rdquo; (ie, a reported overall decrease in susceptibility of S. aureus isolates to vancomycin in different geographic regions). Vancomycin has a relatively good safety profile and favorable pharmacokinetics that facilitate convenient administration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, vancomycin is the agent for which there is the greatest cumulative clinical experience for the treatment of a variety of invasive clinical syndromes, including bacteremia, endocarditis, pneumonia and osteomyelitis. Dosing is as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=see_link\">",
"     \"Vancomycin dosing and serum concentration monitoring in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vancomycin kills staphylococci more slowly than do beta-lactam antibiotics in vitro, and is clearly inferior to beta-lactams for treatment of methicillin-susceptible S. aureus (MSSA) bacteremia and infective endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. Tissue penetration is highly variable and depends upon the degree of inflammation. In particular, penetration is limited for bone, lung epithelial lining fluid and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vancomycin minimum inhibitory concentration (MIC) breakpoints for Staphylococcus aureus are defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Susceptible: MIC &le;2",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Intermediate: MIC 4 to 8",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"     </li>",
"     <li>",
"      Resistant: MIC &ge;16",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatives to vancomycin should be considered in the setting of adverse effects to vancomycin or infection with a pathogen with inadequate susceptibility to vancomycin. This is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=see_link&amp;anchor=H11#H11\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17416566\">",
"    <span class=\"h2\">",
"     Daptomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daptomycin is a cyclic lipopeptide bactericidal antibiotic that causes depolarization of the bacterial cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/15\">",
"     15",
"    </a>",
"    ]. The strongest data for use of daptomycin are in the setting of complicated skin and skin-structure infections (cSSSI) and bacteremia with or without endocarditis due to MRSA and other selected gram-positive pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Daptomycin should not be used for treatment of MRSA pneumonia since its activity is inhibited by pulmonary surfactant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of daptomycin for treatment of cSSSI (patients with simple abscesses, impetigo, and uncomplicated cellulitis were excluded) was demonstrated in a randomized trial that included 45 patients with cSSSI due to MRSA; among these patients, the clinical success rate of daptomycin was similar to that of vancomycin (84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The noninferiority of daptomycin to vancomycin plus low-dose gentamicin for S. aureus bacteremia was demonstrated in a trial of 246 patients with S. aureus bacteremia with or without right-sided endocarditis (99 with MRSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/17\">",
"     17",
"    </a>",
"    ]. Successful outcomes were observed in 44 and 42 percent, respectively. In a post-hoc analysis of this study, the authors concluded that daptomycin may be considered as an alternative to standard therapy in the treatment of patients with S. aureus bacteremia and osteoarticular infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The daptomycin minimum inhibitory concentration (MIC) may increase during therapy and may be influenced by exposure to vancomycin. Among 6 of the 19 patients with microbiologic failure while on daptomycin for S. aureus bacteremia in the preceding trial, the MIC for daptomycin increased from 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    to 2 to 4",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, S. aureus isolates with vancomycin exposure have been observed to demonstrate daptomycin heteroresistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/22\">",
"     22",
"    </a>",
"    ]. Thus, daptomycin susceptibility testing is critical both prior to and during daptomycin therapy, particularly if prolonged therapy is administered and there is microbiological evidence of persistent infection during therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving daptomycin should be evaluated regularly for clinical evidence of peripheral neuropathy and myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/23\">",
"     23",
"    </a>",
"    ]. Serial measurements of serum creatine kinase should be monitored at least weekly; the drug should be discontinued in patients with symptomatic myopathy and CPK &ge;5 times ULN (upper limit of normal) or in asymptomatic patients with CPK &ge;10 times ULN.",
"   </p>",
"   <p>",
"    Daptomycin has also been associated with eosinophilic pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/24\">",
"     24",
"    </a>",
"    ]. The possibility of eosinophilic pneumonia due to daptomycin should be pursued when patients on daptomycin develop new onset of fever, pulmonary infiltrates,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eosinophilia.",
"   </p>",
"   <p>",
"    Appropriate daptomycin dosing is 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily for cSSSI. Minimum dosing for bloodstream infections 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily; some experts favor doses of 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously once daily. Safety data for high-dose (&gt;6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and long-term (&ge;14 days) daptomycin treatment are limited; in a retrospective review of 61 patients who received a mean dose of 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of daptomycin for a median of 25 days, daptomycin was well tolerated; the incidence of symptomatic CPK elevation was within the range reported with lower doses of daptomycin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    for shorter treatment durations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17417169\">",
"    <span class=\"h2\">",
"     Linezolid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linezolid is a bacteriostatic, synthetic oxazolidinone antibiotic that inhibits initiation of protein synthesis at the 50S ribosome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. It does not exhibit cross resistance with other protein synthesis inhibitors. Its mechanism of action may lead to enhanced efficacy against strains producing toxins such as Panton-Valentine leukocidin, alpha-hemolysin, and toxic-shock syndrome toxin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Linezolid has excellent tissue distribution and may be administered parenterally or orally due to its high bioavailability.",
"   </p>",
"   <p>",
"    Linezolid has received FDA approval for treatment of nosocomial pneumonia and complicated skin and skin-structure infections (cSSSI) due to susceptible pathogens including MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/27,28,31-34\">",
"     27,28,31-34",
"    </a>",
"    ]. The efficacy of linezolid was illustrated in a study of 220 adults with known or suspected MRSA infection in whom skin and soft tissue infection was the most common diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/31\">",
"     31",
"    </a>",
"    ]. Linezolid and vancomycin had equivalent clinical cure rates overall (73 percent) and in the subgroup with MRSA bacteremia (56 and 50 percent, respectively).",
"   </p>",
"   <p>",
"    Some retrospective studies suggest that linezolid may be superior to vancomycin for treatment of pneumonia and cSSSI with respect to mortality, cure rate, and length of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/27,34\">",
"     27,34",
"    </a>",
"    ]. However, these are preliminary findings and await validation in prospective trials.",
"   </p>",
"   <p>",
"    Linezolid resistance and linezolid failure have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In two case reports, endocarditis developed during treatment for MRSA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/36\">",
"     36",
"    </a>",
"    ] and relapse of clinical infection occurred in a patient treated with linezolid for the final weeks of endocarditis therapy following echocardiographic resolution of the vegetation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/37\">",
"     37",
"    </a>",
"    ]. An outbreak has also been described in an intensive care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Safety concerns limit the use of linezolid. Adverse effects include thrombocytopenia, anemia, lactic acidosis, peripheral neuropathy, serotonin toxicity, and ocular toxicity. Linezolid can reversibly inhibit monoamine oxidase; when administered with serotonergic agents (particularly selective serotonin reuptake inhibitors), it can induce the serotonin syndrome (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"UTD.htm?42/19/43324\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombocytopenia appears to occur more frequently with more prolonged therapy and in the setting of end-stage renal disease and typically resolves after discontinuation of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/41\">",
"     41",
"    </a>",
"    ]. Peripheral neuropathy and lactic acidosis appear to occur more frequently in the setting of prolonged linezolid administration and may not resolve after drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate linezolid dosing is 600 mg every 12 hours intravenously or orally. Based upon the above toxicities, monitoring of blood counts and serum chemistries should be performed at least weekly during linezolid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17416845\">",
"    <span class=\"h2\">",
"     Telavancin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Telavancin is a semisynthetic lipoglycopeptide that inhibits cell wall synthesis and disrupts cell membrane permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. It is bactericidal against MRSA, VISA, and VRSA. It has a half-life of seven to nine hours, permitting once-daily dosing. Telavancin is excreted by the kidneys, and thus, dosage adjustments are required in cases of renal failure. The formulation includes cyclodextrin, which may accumulate in patients with renal impairment; the clinical significance of the accumulation is unknown. Important adverse effects of telavancin include nausea, taste disturbance, and insomnia.",
"   </p>",
"   <p>",
"    Telavancin appears to be at least as effective as vancomycin for treatment of complicated skin and skin-structure infections (cSSTIs) in adults, including MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. This was illustrated in a trial including 1867 patients with cSSSI; treatment success for patients receiving telavancin and vancomycin was 88 and 87 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/50\">",
"     50",
"    </a>",
"    ]. Among 579 cases of MRSA infection, cure rates were 91 and 86 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of telavancin in the treatment of invasive staphylococcal infections such as pneumonia, bacteremia, and endocarditis remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17417663\">",
"    <span class=\"h2\">",
"     Ceftaroline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The active metabolite of ceftaroline, a fifth generation cephalosporin, exhibits bactericidal activity against gram-positive organisms (including MRSA, vancomycin-intermediate S. aureus, and macrolide-resistant S. pyogenes) as well as gram-negative pathogens (including Enterobacteriaceae, but not Pseudomonas species or extended-spectrum beta-lactamase producers) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FDA has approved ceftaroline for treatment of cSSTI and community acquired bacterial pneumonia. In phase 3 trials including 1378 patients with complicated skin and skin structure infection (cSSSI) randomized to receive ceftaroline or vancomycin plus aztreonam, clinical cure rates and rates of adverse events were similar [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/52\">",
"     52",
"    </a>",
"    ]. Issues related to pneumonia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17418100\">",
"    <span class=\"h2\">",
"     Tigecycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tigecycline is a glycylcycline antibiotic derived from minocycline with in vitro activity against many gram-positive pathogens (including MRSA, vancomycin-resistant enterococci, and penicillin-resistant Streptococcus pneumoniae), many gram-negatives (important exceptions include Pseudomonas and Proteus species), anaerobes, and atypical species.",
"   </p>",
"   <p>",
"    In 2005 tigecycline received FDA approval for the treatment of complicated skin and skin-structure infections (cSSSI) and complicated intraabdominal infections, although approval for management of MRSA infections was limited to cSSSI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/53\">",
"     53",
"    </a>",
"    ]. In studies performed prior to approval, tigecycline was demonstrated to be as effective as vancomycin-aztreonam for treatment of cSSSI in study combining data from two randomized trials including 65 patients with cSSSI due to MRSA (clinical cure rates 87 versus 89 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Dosing of tigecycline consists of 100 mg IV once, followed by 50 mg IV every 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/54,57\">",
"     54,57",
"    </a>",
"    ]. Major adverse effects include nausea and vomiting. Tigecycline is difficult to use for outpatient therapy because of the instability of intravenous preparations.",
"   </p>",
"   <p>",
"    Data regarding the efficacy of tigecycline to treat invasive S. aureus infections are limited. Given concerns regarding achieving adequate tigecycline serum drug concentrations, caution should be used with tigecycline for the treatment of patients with bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition, in September 2010 the FDA issued a safety announcement regarding increased mortality risk associated with the use of tigecycline compared with other antibiotics used to treat similar infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/59\">",
"     59",
"    </a>",
"    ]. In general, tigecycline should not be used in circumstances in which other effective antibiotic choices are available [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/60-63\">",
"     60-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Teicoplanin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teicoplanin is a glycopeptide; it has the same spectrum of activity and similar efficacy as vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. However, teicoplanin has a longer half-life than vancomycin and can be administered once daily with more rapid infusion rates than vancomycin. It can also be given intramuscularly, facilitating outpatient management.",
"   </p>",
"   <p>",
"    Teicoplanin tends to be better tolerated than vancomycin. This was illustrated in a meta-analysis of 11 clinical trials including 1276 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/64\">",
"     64",
"    </a>",
"    ]. Efficacy was similar in the two groups, but there were significantly fewer episodes of red man syndrome and other adverse events in patients treated with teicoplanin (13.9 versus 21.0 percent with vancomycin) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/64\">",
"     64",
"    </a>",
"    ]. A meta-analysis noted a lower risk of nephrotoxicity with teicoplanin than with vancomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Teicoplanin is not available in the United States. In areas where it is readily available, some favor its use for patients with intolerance to vancomycin, while others use it as the drug of choice for initial therapy of gram-positive pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Quinupristin-dalfopristin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quinupristin-dalfopristin is a streptogramin antibiotic with FDA approval for the treatment of vancomycin-resistant enterococcal infections and complicated skin and skin-structure infections (cSSSI) due to methicillin-susceptible S. aureus. Quinupristin-dalfopristin also has activity against MRSA and vancomycin-intermediate S. aureus (VISA) isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quinupristin-dalfopristin may be useful for treatment of MRSA infections of bone, joint, and soft tissue infections in patients intolerant of or failing vancomycin. This was demonstrated in a series of 90 such patients in which the overall response rate with quinupristin-dalfopristin was 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adverse effects limit the use of quinupristin-dalfopristin. They include hyperbilirubinemia, myalgias, arthralgias, and nausea. Administration requires central venous access; dosing is 7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously every 12 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adjunctive agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Rifampin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rifampin is a bactericidal agent that inhibits DNA dependent RNA polymerase; it should not be used as a single agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14\">",
"     14",
"    </a>",
"    ]. Rifampin has been used in combination with other anti-staphylococcal agents in the treatment of prosthetic device infections or bone infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, its use must be tempered with the concerns regarding toxicity, drug-drug interactions and the possible emergence of rifampin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/72\">",
"     72",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of osteomyelitis in adults\", section on 'Antibiotic selection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rifampin dosing is variable throughout the literature, ranging from 600 mg daily (single dose or in two divided doses) to 900 mg daily (in two or three divided doses) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/70,73-75\">",
"     70,73-75",
"    </a>",
"    ]. Additional study is needed to define the role of rifampin in management of MRSA infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702859\">",
"    <span class=\"h3\">",
"     Fusidic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusidic acid inhibits protein synthesis by blocking aminoacyl-sRNA transfer to protein. Emergence of resistance has been described in the setting of monotherapy, and therefore should not be used as a single agent. It is effective when used in combination with other drugs such as rifampin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/76\">",
"     76",
"    </a>",
"    ]. Fusidic acid is not available in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vancomycin remains the antibiotic of choice for the treatment of invasive methicillin-resistant S. aureus (MRSA) infections, although this is an area of ongoing debate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/4,77\">",
"     4,77",
"    </a>",
"    ]. Patients with infections due to S. aureus with minimum inhibitory concentration (MIC) at the high end of the susceptible range may not respond as well to therapy as those with a lower MIC [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/78\">",
"     78",
"    </a>",
"    ]. Alternative agents may be considered if there are adverse effects due to vancomycin or infection with a pathogen with inadequate susceptibility to vancomycin.",
"   </p>",
"   <p>",
"    Given the array of relatively new alternative agents with activity against gram-positive organisms, further study is needed to determine the optimal use of these agents individually or in combination. Important considerations in selecting an alternative to vancomycin include baseline susceptibility testing prior to antibiotic administration and individual patient circumstances including the type of infection, underlying comorbidities, and other concurrent medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will review the approach to antibiotic selection for treatment of MRSA bacteremia. The general approach to the treatment of S. aureus bacteremia and the duration of antibiotic therapy, which depends upon the source of infection, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2011 Infectious Diseases Society of America (IDSA) guidelines recommend vancomycin or daptomycin for the treatment of MRSA bacteremia or other invasive infections (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14\">",
"     14",
"    </a>",
"    ]. There are several studies that suggest a worse clinical outcome associated with vancomycin therapy for infection due to MRSA with high vancomycin MIC in particular [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/8,79,80\">",
"     8,79,80",
"    </a>",
"    ]. A meta-analysis published in 2012 suggested that there was increased mortality among patients with MRSA bacteremia when the vancomycin MIC was &ge;2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    (by Etest) (OR 1.72, 95% CI 1.34-2.21); increased mortality was not observed in cases with vancomycin Etest MIC &le;1.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have not found a direct correlation between MIC and outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/82\">",
"     82",
"    </a>",
"    ]. In one report, investigators observed comparable outcomes among patients infected with high vancomycin MIC S. aureus isolates and patients infected with lower vancomycin MIC isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/83\">",
"     83",
"    </a>",
"    ]. In addition, one group found that infections due to high vancomycin MIC S. aureus paradoxically had a better clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/84\">",
"     84",
"    </a>",
"    ]. Thus, it is likely that multiple factors, including the characteristics and comorbidities of the infected patient, contribute to the associations between vancomycin and outcome.",
"   </p>",
"   <p>",
"    Adjustments to antimicrobial therapy for patients with MRSA bacteremia should be based primarily on clinical response. Persistent bacteremia may be due to a retained prosthetic device, a persistent collection, or an endovascular source of infection that requires surgery. Careful evaluation for persistent foci of infection should be performed.",
"   </p>",
"   <p>",
"    If antibiotic failure seems the most likely explanation for insufficient clinical response to vancomycin, and if the MIC approaches the limit of the susceptible range (ie, 2",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    vancomycin should be discontinued and therapy switched to an alternative agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/77,85\">",
"     77,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=see_link&amp;anchor=H2#H2\">",
"     \"Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Daptomycin, a bactericidal agent, is favored as an appropriate alternative to vancomycin for treatment of MRSA bacteremia (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14,86\">",
"     14,86",
"    </a>",
"    ]. In a retrospective case control study including 177 patients with MRSA bacteremia with high vancomycin MIC (&gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    treatment with daptomycin was associated with lower mortality (20 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/86\">",
"     86",
"    </a>",
"    ]. Emergence of daptomycin resistance in the setting of S. aureus bacteremia has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Linezolid is bacteriostatic and toxicity limits prolonged use although it may be effective for salvage treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/88\">",
"     88",
"    </a>",
"    ]. Given reports of failure of both agents during extended therapy, careful monitoring for relapsed infection as well as adverse drug effects is critical. (See",
"    <a class=\"local\" href=\"#H17416566\">",
"     'Daptomycin'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17417169\">",
"     'Linezolid'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical data do not support the practice of combining vancomycin with gentamicin or rifampin to improve clinical outcomes for MRSA bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14,89\">",
"     14,89",
"    </a>",
"    ]. Short-course, low-dose gentamicin combined with vancomycin for MRSA bacteremia and native valve IE has been associated with an increased risk of nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/90\">",
"     90",
"    </a>",
"    ]. In one randomized trial of 42 patients with MRSA endocarditis treated with vancomycin alone or in combination with rifampin, the duration of bacteremia was longer with combination therapy group than in the vancomycin monotherapy group (9 versus 7 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/91\">",
"     91",
"    </a>",
"    ]. The use of rifampin combination therapy in a study of native valve S. aureus IE did not improve outcomes but was associated with hepatic adverse effects, drug interactions and emergence of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of daptomycin with beta-lactam antibiotics was shown to be successful for the treatment of patients with persistent MRSA bacteremia in one case series [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/92\">",
"     92",
"    </a>",
"    ]. The authors demonstrate enhanced daptomycin bactericidal activity in vitro. Combination therapy using daptomycin together with gentamicin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rifampin appears promising for in vitro models but awaits clinical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14,93\">",
"     14,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of MRSA endocarditis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of MRSA pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Methicillin-resistant Staphylococcus aureus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Skin and soft tissue infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vancomycin is the antibiotic of choice for treatment of complicated skin and soft tissue infections due to MRSA (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"     table 2",
"    </a>",
"    ). For patients who cannot tolerate vancomycin, linezolid, daptomycin, tigecycline and telavancin are acceptable alternative agents. (See",
"    <a class=\"local\" href=\"#H17416845\">",
"     'Telavancin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The treatment of uncomplicated skin and soft tissue infections due to MRSA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Osteomyelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of osteomyelitis consists of debridement and antimicrobial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of osteomyelitis in adults\", section on 'Debridement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vancomycin is the antibiotic of choice for treatment of osteomyelitis due to MRSA (",
"    <a class=\"graphic graphic_table graphicRef57196 \" href=\"UTD.htm?39/12/40139\">",
"     table 2",
"    </a>",
"    ), despite concerns about poor bone penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14,94\">",
"     14,94",
"    </a>",
"    ]. Failure rates of up to 46 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/95\">",
"     95",
"    </a>",
"    ], and compared with beta-lactam therapy, patients with S. aureus osteomyelitis treated with vancomycin had a two-fold higher recurrence rate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/96\">",
"     96",
"    </a>",
"    ]. The addition of rifampin is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of osteomyelitis in adults\", section on 'Antibiotic selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who cannot tolerate vancomycin, daptomycin (6",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    is an acceptable alternative agent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14,21\">",
"     14,21",
"    </a>",
"    ]. A retrospective, observational study including adults with osteomyelitis treated with daptomycin noted clinical improvement in 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of insufficient debridement or persistently elevated inflammatory markers, some favor treatment with oral consolidative therapy after a course of parenteral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/95\">",
"     95",
"    </a>",
"    ]. Regimens include trimethoprim-sulfamethoxazole (4",
"    <span class=\"nowrap\">",
"     mg/kg/dose",
"    </span>",
"    of the trimethoprim component) in combination with rifampin 600 mg once daily, linezolid (600 mg PO or IV twice daily), or clindamycin (600 mg PO or IV three times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/14,98-102\">",
"     14,98-102",
"    </a>",
"    ]. Data for trimethoprim-sulfamethoxazole plus rifampin is extrapolated from experience with methicillin-susceptible S. aureus (MSSA) discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/98\">",
"     98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of osteomyelitis in adults\", section on 'Antibiotic selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other issues related to osteomyelitis management, including imaging modalities and duration of therapy, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3561503\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to management of meningitis due to MRSA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=see_link&amp;anchor=H108515050#H108515050\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\", section on 'Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs and compounds are under development for the treatment of methicillin-resistant S. aureus (MRSA) infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Glycopeptide agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Dalbavancin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dalbavancin is a semisynthetic lipoglycopeptide that inhibits cell wall synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. It has a half-life of 6 to 12 days, which permits once-weekly dosing (initial dose 1000 mg followed by 500 mg dose one week later). Important adverse effects include GI intolerance (nausea, diarrhea, constipation), transaminitis, hypokalemia and hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials have evaluated the efficacy of dalbavancin for treatment of catheter-related bloodstream infections and complicated skin and skin structure infections (cSSSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dalbavancin was at least as effective as vancomycin for treatment of catheter-related bloodstream infections in a phase 2 trial of 75 patients with gram-positive pathogens (including MRSA) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dalbavancin was at least as effective as linezolid for treatment of cSSSI (mostly major abscesses, cellulitis, and other deep soft tissue infection) in a phase 3 study of 854 patients (MRSA was implicated in one-half of cases for which a pathogen could be identified); the clinical success rate was &gt;90 percent in both arms overall and 91 and 89 percent in the patients with MRSA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Oritavancin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oritavancin is a semisynthetic glycopeptide that inhibits cell wall synthesis and has activity against staphylococci and enterococci, including vancomycin-resistant strains [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. It has a half-life of 100 hours, facilitating once daily or every other day dosing. Investigations regarding its efficacy and safety are ongoing.",
"   </p>",
"   <p>",
"    A double blind, active comparator, noninferiority phase 3 study of 1267 patients compared intravenous oritavancin once daily with vancomycin followed by oral cephalexin for complicated skin and soft tissue infection caused by gram-positive organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/110\">",
"     110",
"    </a>",
"    ]. There was no significant difference between treatment groups in clinical cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16779285\">",
"    <span class=\"h2\">",
"     Cephalosporins",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Ceftobiprole",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ceftobiprole is a fifth generation cephalosporin capable of binding to penicillin binding protein 2a, the protein conferring S. aureus resistance to beta-lactam antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/111\">",
"     111",
"    </a>",
"    ]. It can also bind penicillin binding protein 2x in penicillin-resistant S. pneumoniae. It has in vitro activity similar to that of ceftazidime or cefepime against Enterobacteriaceae; it also has activity against enterococci [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In addition, ceftobiprole appears to have a low potential for selection of resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=see_link&amp;anchor=H5#H5\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\", section on 'Penicillin binding protein 2a'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ceftobiprole monotherapy was as effective as vancomycin plus ceftazidime for treatment of complicated skin and skin-structure infections in a randomized trial of 828 patients (cure rate about 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/115\">",
"     115",
"    </a>",
"    ]. A similar trial comparing ceftobiprole with vancomycin alone supports the results of this trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ceftobiprole is available in some countries outside United States for use; approval by the United States Food and Drug Administration (FDA) is pending. Given its in vitro activity against MRSA, other gram-positive cocci and many enteric gram-negative rods, appropriate clinical niches for this drug include treatment of diabetic foot infections, complicated cellulitis (eg, associated with venous stasis or trauma), and selected cases of postop or post-traumatic wound infections. It may be an appropriate alternative agent in patients with drug allergies or in those for whom administration of one drug is preferable over combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Lysostaphin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lysostaphin, a peptidase that disrupts glycine-glycine bonds in the staphylococcal cell wall, can sterilize the valvular vegetations of rabbits infected with strains of MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/117\">",
"     117",
"    </a>",
"    ]. The combination of lysostaphin plus vancomycin reduced bacterial counts in the vegetations more than either lysostaphin or vancomycin alone. Similar findings have been noted in a mouse model of systemic MRSA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Anti S. aureus antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antibody preparations have been investigated as adjuvant therapy for S. aureus infections [",
"    <a class=\"abstract\" href=\"UTD.htm?20/48/21258/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. To date, none has been successful in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest initial antibiotic management of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with intravenous vancomycin or daptomycin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bacteremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent bacteremia may be due to an endovascular source of infection that requires surgery. However, if antibiotic failure seems the most likely explanation, and if the MIC approaches the limit of the susceptible range (ie, 2",
"      <span class=\"nowrap\">",
"       mcg/mL),",
"      </span>",
"      vancomycin should be discontinued and therapy switched to an alternative agent. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bacteremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an alternative agent for treatment of MRSA bacteremia is needed due to vancomycin intolerance or inadequate response to treatment, we suggest treating with daptomycin or linezolid&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Susceptibility testing should be performed; in general we favor daptomycin over linezolid. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bacteremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of MRSA pneumonia is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of MRSA skin and soft tissue infections are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"       \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend initial antibiotic management of MRSA osteomyelitis with intravenous vancomycin&nbsp;(",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). If an alternative agent for treatment of MRSA osteomyelitis is needed due to vancomycin intolerance, we suggest treating with daptomycin&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Osteomyelitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/1\">",
"      Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/2\">",
"      Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/3\">",
"      Choice of antibacterial drugs. Treat Guidel Med Lett 2007; 5:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/4\">",
"      Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/5\">",
"      LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:4665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/6\">",
"      Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/7\">",
"      Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/8\">",
"      Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003; 82:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/9\">",
"      Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/10\">",
"      Lodise TP Jr, McKinnon PS, Levine DP, Rybak MJ. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:3731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/11\">",
"      Graziani AL, Lawson LA, Gibson GA, et al. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988; 32:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/12\">",
"      Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/13\">",
"      Alban&egrave;se J, L&eacute;one M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/14\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/15\">",
"      Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/16\">",
"      Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/17\">",
"      Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.",
"     </a>",
"    </li>",
"    <li>",
"     Cubist Cubicin marketing to highlight single daily dose of antibiotic. In: \"The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, September 22, 2003, p.22.",
"    </li>",
"    <li>",
"     Cubicin resistance should be closely monitored in bacteremia patients. In: \"The Pink Sheet\" F-D-C Reports, Chevy Chase, MD, March 13, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/20\">",
"      Daptomycin (Cubicin) for skin and soft tissue infections. Med Lett Drugs Ther 2004; 46:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/21\">",
"      Lalani T, Boucher HW, Cosgrove SE, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 61:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/22\">",
"      Sakoulas G, Alder J, Thauvin-Eliopoulos C, et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 2006; 50:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/23\">",
"      Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm (Accessed September 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/25\">",
"      Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/26\">",
"      Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/27\">",
"      Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/28\">",
"      Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/29\">",
"      Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006; 42:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/30\">",
"      Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/31\">",
"      Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/32\">",
"      Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004; 189:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/33\">",
"      Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/34\">",
"      Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/35\">",
"      Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/36\">",
"      Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003; 22:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/37\">",
"      Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005; 37:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/38\">",
"      S&aacute;nchez Garc&iacute;a M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/39\">",
"      Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/40\">",
"      Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006; 43:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/41\">",
"      Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006; 42:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/42\">",
"      Senneville E, Legout L, Valette M, et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/43\">",
"      Palenzuela L, Hahn NM, Nelson RP Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005; 40:e113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/44\">",
"      Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/45\">",
"      King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria. J Antimicrob Chemother 2004; 53:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/46\">",
"      Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/47\">",
"      Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/48\">",
"      Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005; 40:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/49\">",
"      Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006; 50:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/50\">",
"      Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/51\">",
"      Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011; 52:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/52\">",
"      Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/53\">",
"      Tigecycline (tygacil). Med Lett Drugs Ther 2005; 47:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/54\">",
"      Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41 Suppl 5:S341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/55\">",
"      Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49:4658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/56\">",
"      Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/57\">",
"      Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/58\">",
"      Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58:1221.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed September 2, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/60\">",
"      Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/61\">",
"      Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/62\">",
"      Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/63\">",
"      Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/64\">",
"      Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996; 37:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/65\">",
"      Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005; 55 Suppl 2:ii5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/66\">",
"      Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; :CD007022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/67\">",
"      Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/68\">",
"      Batts DH, Lavin BS, Eliopoulos GM. Quinupristin/dalfopristin and linezolid: spectrum of activity and potential roles in therapy--a status report. Curr Clin Top Infect Dis 2001; 21:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/69\">",
"      Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/70\">",
"      Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/71\">",
"      Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/72\">",
"      Riedel DJ, Weekes E, Forrest GN. Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:2463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/73\">",
"      Nau R, Prange HW, Menck S, et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/74\">",
"      Norden CW, Bryant R, Palmer D, et al. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986; 79:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/75\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/76\">",
"      Howden BP, Grayson ML. Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006; 42:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/77\">",
"      Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/78\">",
"      Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/79\">",
"      Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/80\">",
"      Soriano A, Marco F, Mart&iacute;nez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/81\">",
"      van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/82\">",
"      Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/83\">",
"      Lalueza A, Chaves F, San Juan R, et al. Is high vancomycin minimum inhibitory concentration a good marker to predict the outcome of methicillin-resistant Staphylococcus aureus bacteremia? J Infect Dis 2010; 201:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/84\">",
"      Price J, Atkinson S, Llewelyn M, Paul J. Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009; 48:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/85\">",
"      Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43:e42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/86\">",
"      Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/87\">",
"      van Hal SJ, Paterson DL, Gosbell IB. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-na&iuml;ve patient--a review of the literature. Eur J Clin Microbiol Infect Dis 2011; 30:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/88\">",
"      Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/89\">",
"      Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009; 49:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/90\">",
"      Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/91\">",
"      Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/92\">",
"      Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/93\">",
"      Baltch AL, Ritz WJ, Bopp LH, et al. Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/94\">",
"      Darley ES, MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother 2004; 53:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/95\">",
"      Dombrowski JC, Winston LG. Clinical failures of appropriately-treated methicillin-resistant Staphylococcus aureus infections. J Infect 2008; 57:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/96\">",
"      Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/97\">",
"      Crompton JA, North DS, McConnell SA, Lamp KC. Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry. J Chemother 2009; 21:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/98\">",
"      Euba G, Murillo O, Fern&aacute;ndez-Sab&eacute; N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009; 53:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/99\">",
"      Daver NG, Shelburne SA, Atmar RL, et al. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 2007; 54:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/100\">",
"      Priest DH, Peacock JE Jr. Hematogenous vertebral osteomyelitis due to Staphylococcus aureus in the adult: clinical features and therapeutic outcomes. South Med J 2005; 98:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/101\">",
"      Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/102\">",
"      Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/103\">",
"      Pope SD, Roecker AM. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy 2006; 26:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/104\">",
"      Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004; 48:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/105\">",
"      Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008; 46:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/106\">",
"      Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005; 40:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/107\">",
"      Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/108\">",
"      Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003; 26:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/109\">",
"      Ward KE, Mersfelder TL, LaPlante KL. Oritavancin--an investigational glycopeptide antibiotic. Expert Opin Investig Drugs 2006; 15:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/110\">",
"      Mercier RC, Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 2005; 3:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/111\">",
"      Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007; 13 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/112\">",
"      Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/113\">",
"      Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/114\">",
"      Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/115\">",
"      Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/116\">",
"      Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/117\">",
"      Climo MW, Patron RL, Goldstein BP, Archer GL. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother 1998; 42:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/118\">",
"      Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 2007; 60:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/119\">",
"      Weems JJ Jr, Steinberg JP, Filler S, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/48/21258/abstract/120\">",
"      Rupp ME, Holley HP Jr, Lutz J, et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:4249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3164 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21258=[""].join("\n");
var outline_f20_48_21258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PARENTERAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vancomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17416566\">",
"      Daptomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17417169\">",
"      Linezolid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17416845\">",
"      Telavancin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17417663\">",
"      Ceftaroline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17418100\">",
"      Tigecycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Teicoplanin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Quinupristin-dalfopristin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adjunctive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Rifampin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H702859\">",
"      - Fusidic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Skin and soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3561503\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INVESTIGATIONAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Glycopeptide agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Dalbavancin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Oritavancin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16779285\">",
"      Cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Ceftobiprole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Lysostaphin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Anti S. aureus antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3164\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3164|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/19/43324\" title=\"table 1\">",
"      Serotonin syndrome drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/12/40139\" title=\"table 2\">",
"      Parenteral antibiotics for infections due to MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/47/15096?source=related_link\">",
"      Vancomycin dosing and serum concentration monitoring in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16425?source=related_link\">",
"      Vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_48_21259="Drug-induced skin disorders OLT";
var content_f20_48_21259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dermatologic complications of the drugs used for immunosuppression after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"       <td>",
"        Acne, alopecia, angioedema, isolated localized exanthem, erosive stomatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroids",
"       </td>",
"       <td>",
"        Acne, cushingoid appearance, ecchymosis, hypertrichosis, delayed wound healing, striae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        Anaphylactic reactions, edema of the face and extremities,",
"epidermal cysts, folliculitis, gingival hyperplasia, hidradenitis,",
"hypertrichosis, onychopathy sebaceous hyperplasia, urticaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycophenolate",
"       </td>",
"       <td>",
"        Acne, edema of the face and of the extremities, erosive stomatitis, mofetil hypersudation, thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapamycin",
"       </td>",
"       <td>",
"        Rash, acne, leucocytoclastic vasculitis, capillary leak syndrome, thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tacrolimus",
"       </td>",
"       <td>",
"        Gingival hyperplasia, thrombocytopenic purpura",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21259=[""].join("\n");
var outline_f20_48_21259=null;
var title_f20_48_21260="Common derm diagnoses";
var content_f20_48_21260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Most frequent diagnoses seen by dermatologists and nondermatologists",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Dermatologists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acne vulgaris",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dermatitis",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Actinic keratosis",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin cancer",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Warts",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benign tumors",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psoriasis",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epidermoid cyst",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seborrheic keratosis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tinea infections",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Nondermatologists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dermatitis",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyoderma",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Warts",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epidermoid cyst",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tinea infections",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Candida",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acne vulgaris",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dermatosis NOS",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Skin cancer",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benign tumors",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fleisher, AB, Feldman, SR, McConnell, RC, Fam Med 1997; 29:648.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21260=[""].join("\n");
var outline_f20_48_21260=null;
var title_f20_48_21261="Hamstring injury prevention program";
var content_f20_48_21261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hamstring injury prevention program",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"3\">",
"        This table outlines a hamstring injury prevention program for athletes at high-risk for recurrent strain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        3 days per week maintenance and prevention:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Warm-up: Stationary bike or light jogging, 5 minutes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Exercises",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        1. Side shuffle: 30 m, 3 x 1 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        2. Grapevine jog: 30 m, 3 x 1 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        3. Boxer shuffle: 30 m, 3 x 1 min",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        4. Advanced skipping: A hop-step forward movement that alternates from leg to leg and mimics arm position in running. During the hop, the opposite knee is lifted in a flexed position. Then the opposite knee extends prior to hip extension, recreating the terminal swing phase of running. The leg is then pulled backward in a pawing type action.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        5. Forward-backward accelerations, 3 x 1 min, start at 10 m, progress to 20 m",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        6. Rotating body bridge, 5 second hold each side, 2 x 10 reps. Advance to performing with dumbbells as able.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        a. Begin in push-up extended position, then rotate to side plank position with arm extended, hold for 5 seconds, then rotate torso placing weight on opposite arm in side plank position on this side and repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        7. Supine single-limb chair bridge, 3 x 15 reps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        8. Single-limb balance windmill touches, 3 x 15. Advance to performing with dumbbells as able.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        a. Balance on 1 leg, rotate trunk to touch cone alternating right and left hands, twisting at torso",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Eccentric hamstring strengthening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"3\">",
"        Include in the prevention program a progression of eccentric hamstring strengthening exercises, such as the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\" colspan=\"3\">",
"        Nordic hamstring exercise (\"Nordic lowers\"):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        1. Kneel on the ground and stabilize your lower legs by having a partner push down firmly on the back of your ankles or by wedging your feet or ankles under a heavy object",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        2. While keeping your body perfectly straight from your knees to the top of your head, and with your hands placed just in front of your chest, slowly lower your torso until your hands touch the ground",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        3. Push yourself back up to the kneeling position and repeat for suggested number of repetitions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"3\">",
"        Note that this exercise is challenging; progress slowly",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"3\">",
"        The following schedule can be used for the Nordic hamstring exercise:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <strong>",
"         Sessions per week",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         Sets and repetitions",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 1:",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2 x 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 2:",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 x 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 3:",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3 x 6-8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 4:",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3 x 8-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Week 5 (and thereafter):",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1 x 12, 1 x 10, 1 x 8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Heiderscheit BC, Sherry MA, Silder A, et al. Hamstring strain injuries: recommendations for diagnosis, rehabilitation, and injury prevention. J Orthop Sports Phys Ther 2010; 40:67.",
"       </li>",
"       <li>",
"        Mj&oslash;lsnes R, Arnason A, &Oslash;sthagen T, et al. A 10-week randomized trial comparing eccentric vs. concentric hamstring strength training in well-trained soccer players. Scand J Med Sci Sports 2004; 14:311.",
"       </li>",
"       <li>",
"        Arnason A, Andersen TE, Holme I, et al. Prevention of hamstring strains in elite soccer: an intervention study. Scand J Med Sci Sports 2008; 18:40.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21261=[""].join("\n");
var outline_f20_48_21261=null;
var title_f20_48_21262="Lesion complexity in UA";
var content_f20_48_21262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Determinants of coronary lesion complexity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 210px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lesion complexity (0 = no obstruction; 1 = simple stenosis; 2 = complex stenosis; 3 = thrombus; 4 = total occlusion) is related in an additive fashion to the clinical setting (worst in post-myocardial infarction) and to the severity and timing of the last anginal episode in patients wit unstable angina (UA).",
"    <div class=\"footnotes\">",
"     Severe class I: unstable angina without pain at rest; class II: pain at rest more than 48 hours before angiography; class III: pain at rest less than 48 hours before angiography.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ahmed WH, Bittl JA, Braunwald E. Am J Cardiol 1993; 72:544.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21262=[""].join("\n");
var outline_f20_48_21262=null;
var title_f20_48_21263="Lipoma terminal ileum SBFT";
var content_f20_48_21263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80114&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lipoma of the terminal ileum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 321px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAUEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3BdF0vPOl6WSOQfsUQwf++PYVIdG01iWbStNLA5ybOLOfX7lXY+AATtyMHHI4qRSEPBYtkgZPWgCkNF0wNxpWmbhwD9kiH1/g9arXGhabJIW/sjSmdsKXayhJx/d+50rZjJ4HU4+bPXNOUZBJO0FcnHWgDB/4R7SON2h6T5i8BjYwfkPk7U1fD2iuSZNE0c7iNzHT4Tux/wAA9q6DblR82VPPX8KiZMLwBuPcdR/SgCgfDGiyli2iaQXJ3ENYwHn3O2lPhfQDGyPoOjeWx5U2MJGfpt5rbTBAj746HqKFA3fe+XlScdfagDGfwtoB2n+wtI4wB/oEPyn0+7ULeFtA3k/2DpGMEZ/s+D8R93Nb64yRgEbcY55FMcgkEnn/AGe/saAML/hGNC3Kw0LSdwOFxp8JOcdjt9Kgl8NaCjMF0PRwpXZj+zYBwM/7PTn9TXQdixABxnAPT2phQNubkAnuOpx0+lAHOP4a0MjadC0cgcHOmwHn0+5UaeGdDwQNC0bgHJGmW/T/AL4xW9Io5I5BHPbIFQyHceOMH1NAGDJ4V8PsuxvD2hEBtwB0q3Iyf4vudfelPhvw+A4/4R3Q8FsgNptuAx/7461tMp4HKhR6DmoHwRgjjjqBj8PagDKbwz4ekQF/D+iOuMfNpduQV9vk/OnDwz4f3ZHh7Q8bgdw0y3HP/fH6+1aSE7guc7eRz1HvUhyW4JJOPoM/4/zoAxl8NaAOR4e0NHP/AFDLcZP12fjSjw5omAz+H9DY+h06349h8la5IZWGMgjI5oOAULD5QuTlv5UAY0nhrw+c/wDEg0Ejqf8AiV25x/45WXd+H9GQsDoGgAdsaVbnr7eXXVF1wzFs46k9ax9TIwzNuBAB4B9e3t0oA5afRdG3bRoWhqM8f8Sq25J47pVN9I0ZCV/sXQjnls6Xb4J6f3O9ac8jPtVtoYnLAdP/ANfeqxfaynaA4UBSR04/rmgDIm0nSH+UaLowXjIOm24/9krNu9I0pYSx0TR+uMDToOPfOyt8jLbcj5eB6fT61l6uSFyeSoz+PvQB438Q7e0hiPkWdlDuYf6q2SMj8gK4BVUMcouPpXffEMlyDnndnpiuBbge9AGzpKw3bLH9mgLAgf6peR69K6B7C23oi2lqSMH/AI90Gf0rA8JL/wATMZJwVII9a7l7f73PXvQBhahpFjcLgW8K44BijVCD74HNc5faDLAu+Nd8ZHBA5runt2llC4IY+nb3/wDrVesrT906PuODn0/KgDx14in3lHHtTMDPQflXoHiXw8LefcIyI3G/I6EetcXf2clpJhh8rdD60AUsD0H5UuBS44pKAJIgM4IU/hWnZaeLrIjRCehGORWXHxg10nhKUJqCoTjfgfjQBzMsZjkZGAypx0pmBW/4zsDY61Idu2Ob514xz3FYOOKAE/AfkKKXmigD9Hg/zAD7vr/n8qepDKGyAT3I/Sq6SbsYzgEZx61KrbdhbBHr2oAnyWbJALdCwOMe1SDAUcYbJPPbFQ53dRzgnp+ZpY5Rj52OM4LH6UATgjqDtAHzHuuaEBZsgALnqO/vTA2HIVh2xu70CRVJ5xjk5Hr/AJNAE7ZKnaMAjt6H29aXcxJViWHByO/0NQebhh1BB6/0P+e9OWUMGBOee56+lAE3mnb06cYx600nBIYAnH4U3ccjdkHpg87famh2+XC984P8P1oARxtUggbQRn3FRTSYfg/pkEe9OLY9sdhz1qM4UZzxx7YoAjeTO4OQF6/U0xhjIJ9zz19xUnBwGHIOCP7ppCeA23IHQH+f1oAiY/KoPv14+tVHYFsrjkZPvViXJzyCT0Pr71CxXP8ACB2z1oAY7seB0yOcfjj+lLES2AFGGOFz09TVeaUAhjkrxu/xx+VAZz35zg57+4/CgC0WDgtw654LdetRSMVZiRnPJ7/jUYlLMARz2Prjim7v3jsvOAFP40AO3cfIMZ9ehHXisnUpQSN27p8uR0PrVy4lWNAUJGR168Z5/CsDU58yZVmO85wOw/8Ar0AUBtbcM4CYJP8AnqaJYiwP7oZODx198VXSVPMbawK+hPpzj/ParcL+ZjBORznHNAFO5VfLwpIYHk54PuKy7+PMTxHk/wAII6VrzOuWQ8PgnOODWJqU4KHnJxk8YNAHlPja0ebzABwpPJ7f/qrzZoiXxx17dq9Y8X3Cm1kcx4xkr71xeh6QNRZXXCuXyUJ/hoAf4Z0ieOWO5Zc+gx29a9Bt7DzI+cjAzx+uai07RmhjWNcAr3962LS0uQNxLDjBGOlAGbFpzrIWK4AOD8uRWrbWp3EbQQRjgVfSKRQPMGSOQe9XIYgSGHHRvSgDKutOjvLQxyqMgfKxHSuE8QeGRLbyQqm1v4e+D/nivWjbhJgeQOp7g+3/ANeqWrWHnIZNqggY+v8AhQB8xXltLazNFMjI6nBBqD0r2Xxr4V/tGINFhbpAWU7cZHoa8lvbKWzuXhnQq6nkHuPUUAVgucDmtvw7tTUImzjBHPpWOBWhp0vlXCsOO1AHpeuaTBrdgIZeHGDHKByprzPVNAv9OlKSxb1HR1HBFeqaNdq9ojA/Nkde/wBalu4IrsfOv1B+nSgDxXyX/uvRXrH9kp6JRQB9aK4OwBgM9MD/ADk1IJNpGDkHoeg+tZyShHGGUg9Pcev9PxqKW9BcoWXevGMEAH0//VQBshgsRAzk/hxT1k524YDAGPasu3lL5H+1uOefw9DUyy4yCQcHI74H17UAaPn4UqSWAOenQf40wyKjlsZIIwxxg+mKpiUDg5GeRx0/H9aa02wAgjB4O0cD1x7UAXPP5IJySDnP14P9KmjlHckdM/Q9cVlGZcffGG43Dpn/AD+VWInHdjz2zyRQBrKF2ovBA9M4xSsAUbywd3v/ACqOE/KCMNs6Htz2qZ3IHXGM5FAEbHcowwwOMdj7Z/rTcbSwILHGMY6j0pZHJRgQWzngjn/9VVg+5iBlcADk9f8AHjFAD3YBgwZRzwcfgDUchwVLttJ6nrz60x2Y5yQRg9+n+FRFsnDEADk9s0ADsSARyw5ORnFVJnUbiSdpbn2+houZfmYBjnOTgciqd1OEB4HH48f5/GgB7yLvOwhGXljnJOKi80iRsbtuMA/0/CqTThTu3Y54HbGM49D6VmXerohOHPQDg/1oA6H7RtJUtxgYIPT6etQyXAWIohGTknH+ehriLvxK8bZyM/Wqn/CTxSbg0gBP3Wz0P8qAOoutVAkJJDrjGR1HtWNLdB2dtyMuOduSVrBvdS/d53HaR/Ccn61kXmtrFIsfG5+Dg/mPagDqLR43lkbgZ54P9K0I5SkfzY2g45788ZrnNOmV4xsIbPU559/xFaRmG1S2Rgd+xHAz+tAFy6w0fDBm759PrXNanOqnZknBzkHOPetm7kITG1hg5zjqcc4rjfEEpjyVySckHp+NAHKeIZzdmWKP179Kf4Xt/s92jqRnOMDjB/wrkNZuZnuXhjZyS3GDyTXaeHNPnhtVMrfMfm5OOT2oA9Es4Y2jWQEbX6nP+fStGK1ON4XIY4x6/UVjaEVhK5dhn17iuttljEe/J5+7yMH2oAqPaDawKAIeuf8APSomsl3ALvJIwMfyrYXYWDbsnJ7cD/P50hjJUFmDMcZxkc/SgClDE+AhYEMMYJ5X0IqYwoA+CuCcA+vtj1xzVuPy85IBz0I7015CcEhQF4AznmgDBuNOjuIiG3AZ45yTXC+MfCkV8kr+WNwy24Dnp29a9RZwQykHcV4X1rJ1GMMHGMk8nigD5h1TTZtOuGjlGVzw3Y1XhODnA4r0j4kWKLZvKMFlbOAOleZxNgkZFAHc6Ff4jUI4Unueo/CtsXasM/KAQSR6159Y3Qg46E8Z9K14dQVhl5l98HBoA6j7W3qv/fVFc5/aS+q/pRQB9Uy3jMAqHtjA7DuKjSaRpwz9Mn5sdPf+tZUUxlPzHJxxwR/njP1zVrzEjO5CMjkZGB7/AI80AdHDJJGFGQSOjYI5+meKnM5KZJjTuOOPpXOJfKFABzngA8VI1+jD5iQc4HfH0NAG0tywx8y5zkDJBAPpSec7qQuwHHGCT/SsdLlXcknJwcE1at5JG2bSNy8IO2B3oA1PMY8qq/JjADY/Hp+lWLZjuUYU7cjlsD+VZ0RU7w3JJzkj/PIrUghUuxOGUAKM9c0AacUh2LkDK4B+f+YxUwlLcFCMH+FwKpB9vAcfNgkrzz/hUil2bbxz1oAkaRyRheegwR05wOv+eagZiAoEZ54ADr6U2R2VWBYbhkknnHv9KqSHOcHBOOnOB0OKAHGYhULRbuerOBz/AJ/CoZp8sXCjaeSS/IPvx0qrPOBjdw3thsVm3d+qltpUgH1oAt3N22wthcr0IY9Prisa61DylUl484OACT/QVl6xrSQRM0jKFHOWYD9a8v8AE3xAtIGkSKQzyHjYnOOe56UAd/qevEfcZRn0z/n2rlNU19drEzKOf4Rkj0715Pqfi/UryQlWEKdlHzH8SaxptQu5gfMmds9c0Aegap4kVc/vhz8pxxgVzV/4nuJGbymKAnviuaZ2bqTTD9KAOgi8VakuQZy4Pr2/KrEGvTSSA3ID++TXLZNTwy4OG5FAHrfhvVw0CbcYzyc5/PNdVBfIV3FQx+7jr/OvGtI1T7OSN4Ckfhmu2sdZTy4xIeg5NAHVS6hAf4QCAOCODXJeJ7uJYS+0dO/Bz/hUd/qkZQlZAB168fWuP1jVVnbaGDKO2O9ADNKlt5dUDzLnnAr0fTLq2KLGqsSTzx0H+FeRW0ypco57GvRfDtys6hmGOent/hQB6Fp3kSBccBs564zity3eNNhQbiBjknke1YWmuoMYVCVxyOp61p28u+OOUiJoX2lWQnGDwOvXtnFAGtC6nCyPIT93G44q0EQKWLSDGBjufrxWbGNoBU4btj1/xxirdtISy5+YjO0HnP8A9egCfBwW83k/7Oef0pjCQnPmZxjqOf55pzv8wyuHYYOfTNVp2VVLZU8kNnucUAExHfYwf+7/AAj/APXWRqE20AZjUYwQCf04q1NcKd+cB25wTXMa7feTDKxIBAIU59KAOE+JV0H0xwCuS3Zuf5V5Tkg5ziun8Y6rJezrEx+RDn6k1y/QUASCWl8846VDR60ATee/qPzoqL8qKAPp+11mMrjeCT0+gNW570SQkx4L45B5ye5/z7V8/wCm+K7q2IE3zjGMjg109h42idQHkZW77u5oA9EbXtikAtx26j60WWvea+ASVycE/wAq4uG4gnk3s5IfkKDwKngjiPzQylSpJ55oA9V0i8SXcznA6jHIz710lo+VQBeCcDHp/wDWry7Qb598a4yp9OOK7rTtVQFPlY98ge9AHXW0RG3cSD2Ofzq/EVAXIBz2HH4+1ZdlKJEDIwKscqfTrxVwSKxzjBHc/qaALqkEMQeCeM05pMI3IU4w2R2qi1wBjbkAjgHtjvVO51BYkOMgHjk9D/WgC9c3SgNyAw5K9vwrMvNSRPm3DaB3Ncp4l8W22m2hmupQkaA/MeOc14p4i+Kd9fXD/YIhFFnh36n8O1AHt2ueJLS3UtJMqgE59/fNeXeJfijBGzw6erTyAY39FH415Zquu3+pEi5nYr/dXgGsstmgDa17xHqGsysbqdth6RqcLWIT6Yx7UGgKWOAMnPSgBPSk9q1rDQL692lItqk4JbiujsfBWVJmZy3cdMD3oA4bBJpRGx7V6MfB0WAVVhx29akTwzCqAbPrn1oA8zKMOtNziuz1bw6Yg7xduwHFcrdWzRMdwwR2oAiSTGM1ci1CVEKhuCMYrOoyaALk928udzZqs8hzUeaPSgByt8w+tdP4bvbiCXbENwPUYzj1xXMIhzXb+DYlZoyQu7pnP5UAes+GWkkto2lQrnHUYwOgz610EVpCHaby4vMbktz36nHQH3Az1rO05WjiRTyAAce+P/r1rxOocBW2/MBjPt15/lQA5YBk8/MRxu/hqaJAkeeASOT1P4VGX2/h2xmhpgu9epODkD1/lQA5m+cKSxA6c1SnlAlOGIG3kHr3HWh5VDlVGSeMHuaqXUoKAhcn+Ee/cUAVdQuQqgJnb/e75HNcH4ou2KnLcKK6e/lBZs7zz2PGK4DxXcqYXLMCWXAoA871GUy3Ujk9WqmalmOWJPU1FQAetHaiigA4/vH8qKMfWigCUH3p30pgpR1oAvWeoT2vEcjBT1GetX18Q3igbGAA6cViCnAd6AO10bx1PZuv2mAPj+NDgj8K67S/HVnc7R9oMT/3ZDjn+XNePBT6GjpQB9KaJ40gjVVaUGInBKnpXTp4usXiJ3rk5+YHg18lwXU8H+pldPo2KtNrF8ylTcvjoecZoA+ltW8e2VmhaW4RAPVuv4V5v4n+KskpaPSo9xxjzXJx+AryaSZ5W3SOzH1JyaYTzQBoatq97qs3m31y8xH3VJ+VfoKoZORSVLDbyzH9zG7+u1c0ARU5FZ2VEBZm4CqMlvoK0LTRb+5nSKO2kBY4y4wB+Ne1eAfBEGnWiSzKr3j8tKV5wfT0+lAHmWh+BNV1Aq9whs4T/fHz/l2r0PRvAdjYhd0JlkXqz9G969Fg00DggD0OM/n7VZ+xg4Bzk8bR1P8Ah/KgDlbfSY4lXbGoC8DI6/59KsNYqNoCgEdDjqK33t9xAG5Wcfxe3cUzyAE2jGxuDnAI55oAw/smGAYAduB1qKWy2qVwG45HQV0DRAKFIION3XOPX/8AVVa4i4A+VWHfGMelAHCatY5YflyOtcPr+jhxIwX5xkn0H+fSvXdSgD5Zjh/Unr+PrXMappquSBg8fxUAeHXFu8TkEYx61AR1rv8AVdC82VyPlw20cciuY1fRbixAdl3Rd2UcD60AY1WIIDJ061GE5yav2UhikUjOO4oAt2mnMygkZbqB3rrfC1pJBcIdoweRkDiodMtxOgeNQMnPHSuhsbMq4I+VlOR+FAHe2R8yEEknjOQOT9BVwZChgNwOOcfr7VjaRcM0Yjf+H5gen1P0rRE+CCD0+UE9foKALjy9VfJIUYx1H19qiecDk5yBnac1Te5+UdcAdhg/X86ryXBUtzjjIB649aAJ5JMsA+3ceAQePaqV5cEBsnOQeBzz/kVDJKcbE2nPOS3es++uAqspJUnn73+elAFHU7kGNgCenPPX/wCtXmXiW+D7olwRnrntXTeI9TEcZUNgDseea86vJjLK5J6nNAFZjx+NMpT+tJQAe1HNHrik7UALz7UUfL70UASD8qlhheZwkaFmY4AHer1pps00gRImJ9cV1nh7QpYpgzx7WOOo5FAGfp/g27n2NcMIw38I5atOfwva2lrukRyeeSf84r02ytCLFi6jOMEhePwpI9P+1WUwnRAh+4CP1oA8i/siCTKoGDZ4xzx/U1BfeF76CMSrFvjP93qPrXoUWliS7YWkXzr0yf8APNdRpVo7KUmGzPYjINAHzvJC8blHUhh1B4NMx9a+idW8CWWqR/vLbkjAYcEHp19eK4HVfhbfWmWt7jzUJO3K9s96APNACanitppSBHG7n0AzXdaV8P7hpN144Kg4CoOD+Nd/4f8AB0dsytIMIvYDr6UAeWeH/AusarJGzwG2tieZZODj2HevYNJ8I2VnpsVtHACFJbgZJz3z3/ya62zs0ghBKFlxt47H6VajUGcc5weoOf8APNAHO6X4ch3rmFWUHp2I/DvXWR2iIu2MYOMcDjPoav2lsyKFKcdBjnkH171P5R2ggBgT82R1oAoxQDZuZS27t3pphYBWC8HvjIGP884q+0Qz8pBz0PqP8aR48gFhkNyBnGR6YoAyjDk78FVBwU+gpwUCMjAJAwQRg/8A1qtmLcG5wM4BPVfoO9AjUEMzfOuO3UD3+v8AOgDPnjABEeAh6/L1yPT8qzriBgMrwR1HX8q3JIwrseQuMYxxnP8AnmqkkBK7cFt3zDA/z0oA5+5hHmZwdpGME5/P3rOu7bcvIJyPunjA6V0c8JY7cDJ6+/rWXNGT854HIPOASO3txQBylxZDzM7Qw6/d4GeCc1UutJWUMoUndnjHX610lzbhWHKjvjPJ4/wqjNxgp93APPQ9gc/hQB5prPhRYXZoIygzyPSsJtPeEnKbcHnnrXrFwgdirEYwQf8ACuX1W0BIJAyOxGOaAK/hV23FZGyhOOemK7aGAKm5FOcn15x3/wDrVw+mqIpgyDJTggjrXoFhma2U9CQMjPAoAiT5Z0O05yT8vJI960ILjagJ3bOh2nke361E8OxiQoAJ7cCmThmHAXg5BPrQBNLKApz0J6+v+BqB5xg8ofQY6fSobiVUj8sD1464rOiuBI+GckjJYdCKAJLifZjdgBj3HSuT8RawbdHDNznAAHetXWbyODfI7YRRwe4FeVavqD3t28jEhCflX0FACahfPPIWdic84rNYkkmkdiaQGgBe1NpT0pKADsaTtR64ooAdx7f5/Gik49vyooA+h/Deix+QrBAGx94f5/Guyt9NtVO9kThd+ePm9aw/D7EwIHOOAMgc/SujtPnkAIAyepOM0Aa+n2lsyBWjBBHQ1HqWgNKyrAPkxn5RgY960LGIKQSMEjuMYFb9lGHVCFOw/eB7/SgDmNJ8NW9srSeWCx+8xHTvkfSnXWkRmQ+WAFwCR6D/ACa7DbkZ+XapzycZ+tZuoGSKF/vY424Gc5PegDJtLclSJVDkfMcnuO+KlNissTrInzMMg98GkhmAnKvwehYdB7/41sW7RsOS24/MSOMHH8qAOSOlrbyYQZ4znHSnraBB0OM/h9Pat+8jUuSxBU984yajWKJ5v7o+7uPQ/WgDKEO2OTBYJ0PGOewNJBCWkzs+cHBJOB17/rWpcxqrLnJK8AE9evekihEeHIIyAAGHbHFAEojwc7iG+XPbBzSjYCFGBxnC8H3qs8rAEkAOPu5756598UJOsqq2RvOB05xQBYIH3gWJHGCeKHTGeCwGGOf4aEdW3bVGMd6VCEC8A89Tx+FADfK3fO4AI6gdvU0zBBXjBxnHp7/59afuGOTk7T25BxVeWRt27ILAcenHTFACbQowCqqV4568/wAqYwEkW7seAynA/H2olkDOF4AIG3tnrz/9akMqsq46dAR37dKAM+5jYuN2C3HPTPsKz7lB5ZK4O38yfp9K1LhlVm6HaMc9+KybiYKSoPOeuOtAGXfxjbuK5Ge3GOOvvzWNc7gwQL1Izgdj/WujvFKhiMbcbsEcEdsVzd6yiQo+4Lwcg9fagBioHQgHk5wCO/8AnisTVYC6MX5wOB0xWwt2M4Yhmxw2O/8Aniq19Mo3HaD2z6Z7UAc2kHzlnA29+4rq9AdTGU7DoD3Jrn7iZCSduP8AGrOk6iEnwehYZx/SgDrpFDnPTrkkdumKgljBVyFz0z9PaliuUMatnPFRXdxiPCsvsB1/zigDGv2WMlQwYDgZPX3z61ivcqC756evatHUH81yxJIPfjrXG+Lb0wWzoGwznaOegoAw/E2sNczNDG2Y14J9TXNOd3SnTNnk1DnmgBOtFKegpKAF7UlHakoAKKKSgBaKKKAPqDw/zawlAOg6fTnrXVWMAbOQTnA69PSuE8DaiNQ0q0kVRv2qT6ZI/rXpWlw5B3ZDZ4J4Ax/WgC/aFpW25+bI/H2rdtsqnRePYgYqhHbKpIc8D+Fe9a9syFCFAHoCvb/P40ATQpIISwK8dQR0/P1qSS1LqyvtIwRnHTnoakTyzKMevytnAA7/AF+h4q5HyuVBCntnGD/n0oA52bS1DZUJnJwfTniqi28yzccLk/ifSulnQbs9FHHAzj8fr+NRGJXkdskge365oAwNRRwoLgq2MfKRWUkoEwKbmHA5OevQ81099ECFVhnByQa56aDy7hmIxgHaaALXDl2ZV6DK+nsPwqC4chxHkAYB+U8DPUc96Rz5YQYYEY3DOOCe3p9OtU5nIQLvDD0P+Pr1oAj83k5UAsTx+PalBLP93IzwAePpVVZMHHGSRkjkZ7ZHTmlMohjZnyO4/of/AK9AGiZOQzuytgbdx/SqV5rUaqyhRnjr29qwNX1Xch2YJBOBjOT6VzdxqvmfeYsP4h6+v/66AOrk1l1cBXJXGAAevvU0Wu7cZG4A4dCcA/8A1s/zrzy61La5KNjqMDrVIay/XexPAzQB6zHfI52lWU8fKx4q1jeg/eL0yTycj29a8nstfPmYLsOmD6eldNpOvBlAMhaJh0HT8P6igDq5sOdxI3DljjJBrNuFXdJyw3DjjBB/+tUM+ohgAGXaRnrwB0/Kqj3u0nBBweCTk0AOvGCxE/P05wfbr7c1x+ozMJHyzZAIJ7H8a6S41Py4SrBCevT2rjdSv4yXYlEYjrnI/CgB6TDzApbqOvc/hRKzyRjk8HAweB9aw1v4S4bzixznnsa14ZFeIlGDY4JHzfWgDNvQcncM46VBYvtkGRwfy/Gr1woK7s/IeOeM+3tWPO4jk4OecAE8cdqAO6t5ENsnIYAHJPB7dahvrpAjbiO5OeB71yFtq4VfLMinPXB/p6UX2pHyzltyjgk8/hQBc1G/SLcecDrz09q841q+a7umYn5FOAK0tW1EzAjJ2sT1rmp35wD9eKAI3OT7U2ij1/lQADoKKSl60AFJS9qTFABSdvWlo9qAF/z1opM+1FAHpvwh1kwan/Z0rDY/zxr3OOoHv3/Ovo/RnXaCrKRnOcdffivjOxuprK7iubV9k8TBlPv/AIV9L/DzxOupaZDcHksvzL/dPQ/hmgD0yNgwz2Y9egFaNu7Yw33s8Dufx9ayLKdXO5hngZYdM1pQuqEAt82MkMCc0AbVu4HJJDEcmpVkUMRhiVAzx1rNibkFXwc8DOc+1Ww27JPyjaRkk/KD0+tAFlWV8Nyc9APrjJxUkSJ5ed2SehHt6++e1RBdoy5BXHX1GelWIFxgg7R2OeR6UAQzwBv4VHcjt+FYuo2jHcWQZxzj9MYroZW2jeeOPXv2qvKu6EjcBjsR0FAHCTSt5m3Hc5BOMDufeqVy+7JAAUdBng+351q63YlZTJbhiQRlema5xnLyr5UjADkgjt/9cUATpLFbhvMO1l65Jz+tYGp6gu4nzBtPA4BGPSjxFqCxKUB5J4I7+h/nXnusa+scUgyCepzQBratqkaKypJk8jBOM/SuO1TW9jlmce2OKxtR1oyglWIJ/OsC7ujMcsfoKAOls7291W/jstNgkuJ5M+XEv3jhST+gJ/Cs5NdmDZfBHcHv9PSvZP2P/DRvvFGp+I50zDp0X2eAn/nrJ1I+iAj/AIGK8w+M3hs+EfiRrOlomy1Mv2i2HbypPmUD6ZK/8BNAFL+2QTuBJfHOOMVuaNrQyFV+o59jXnfm+lWrC7eKXKttz3NAHtmk6qZIjE5GQPlGc/hUs9zhd2NrAcZ/rXnnh7U2dlMpXGQGPpXT3F38vIGAT7kGgCzcXBAf5jnuR3x3/wDrVw3iu5MTKE6MfXNbkt5uDFjg5PI7cf5Fcd4pcPJExPG3vQBnfbWZyxY59q3tC1Z1k8tjn0xxXIF8evFXtMuoopwzjkdM0Aei6hexx2pYsDxn0P41wesao0zbVY7eh96brOrSzhY1JCjng1iu5bkmgCyLth3PtUyX8gTG8kEY5rO+nFJQBYnnLE8nJqv3o+tHQ0AHbrSfWigUAFL6UlA60AHail4xSUAAo7UUlAC/iKKOf7p/KigCyK9C+GXiCHT99ncNt3Pldx+U57V570NPQ4YUAfYmiapHJArfKwZQM9RiujjuxIjNGcjPJ9R6/wBK+Z/h14tZWjsLyVtwPytn7y+n1r3TQ9QEwikjbpjOD/n8qAO0tiygAD2GTj8R/hVuJiW25bOcZHUe9Z9tLu2EjIIwM+lX4QI0bnLE89se1AF+GQxx4/hz2/SllmcBwhLHGVwvGfT6VWMhCpjaMDAIGOlSwhySd5HGCVOOfpQBbjLGIZIY8Z44PHOKJSCGAyM8nucf41GrHGMvt9fSq0l3mQoOCAME8Z7UAV723X5lIO3ocnOOe1cxqunFN8y4zwScdfY11iypnKkFT69PpWXqiqIGIAZlG3joRQB87eMtWJmlGdqknAJ6/wD1uK8x1O+eWVgGOOh969E+KelNA01zGUX5txU/XqK8mmbqRQAPJyagZs0jUw0Aen/A/wAe+JNB8W6DoWlaiYNJ1DVrdLm38qNg4eREbkqSCV4yCK4zxf4s1vxhqa6h4kvmvbtYxEshjRMICSAAoA6k9qt/Cv8A5Kf4Q/7DFn/6OSuWoAcDmnqcd6izzS5oA2NIuWimUZPJwBXX3t7tRTuIAA71xWkRGW5XbklfmI9hV7U7p3kKhs+hx2oAvPeu0nD4B7ZrE8RSM9xErZ4Xv1zSJKiuDMeBz9ap6hc/aZy4zjpycmgCqelJk5o/Ok6Y60AKxJ5PWkzScUUAHekoooABRRRQAUUUUAFFFA60AL2pO1A6UUAFJRR25oAOfWijcfb8qKAL0qFHIIwQSOfWmV1/ivQ5La5llWM7CxyQOM5rk5EKmgB0MrwyrJGdrqdysOxr2r4c+L47yCK2uJNlwowV6A+4rxGpInK4IJBHIIOCKAPtjSrtZbdOd2OcZ7DFdFbtxgnOMgkDOeOc5618/fB/xd9utorW6l/0y34bPJYdm/z3r3KyvA8ezPzHBHt6Y7UAbUZz8jYYZztz0/yKmUrgqVUk8n1P+HFU45iZM4IIx14BFSSTsCcqpOM8HJNAEs0qgFlB+Xkkk9P61h3TM7EqckHPHGBWhJIwAG88ZOR/npURgaX7wGccAdM/0P6UAUHZpIRwwGMkD27j/H3ptxcqyAkcdiO49P61oSxgLjGMEZHYH6du9Zd0gKsu8AsOrZ4HpQB4h8Zhs0qaInqcA8evSvDpOD2r2T44vMqIjL+68wDcPavG5fXvQBCw/Om0ppKANfwdqsWh+L9D1a4jeSGwvoLqRExuZY5FYgZ4zgVjdutHekJ4oAU0gNFJQBdsLxrRzIhwSMUtxfM7EgDce4FUPyo9u2KAFdyx+Y5+tNJyaKKAEo7UGkoAKKKD0oAD1pKDRQAUUUUAFJS0UAFAooHtQAUlL2pPpQAf1oNHrQelAC4HoaKP++qKAPrHxX4aS4MnmRgqeMkcj/PvXhnjrw0+kXRdBmNuTgcD3r7EvbFZlAwCRxkdsV51448MRXcMimP59pxkEUAfJ7DBpBXTeL/Dc+iXO4ofs7dDj7vsa5kjFAG54R1U6RrUM+4hGwjEHGBnrX1X4V1OO7skdcPuODznBz+VfHAPFep/Czxe1oxsbqcqQMxknAYDt+FAH00ZciMhMqp5x0H0qzHK2SMgjJG4c4P0/SuR0jWVniQh1yAeOCDn0H4V0NvdxhSd8Yc8YHT8aANOFNxAIbthepx6/WmiQ7QQvOduOhBHfiokuD05GByD6/1pTIQwJAJByPb1oAkly4+U7gOh3enr3rF1a48pBglXYcsen44q9eXAER5DMvY964/U7tmVirhkK88/5/zigDgfiBZLq8Ekbg4z8px0PpXid/pk9pO0cyEY6N2I9RXvmpxmc4Kg5PAzgZrDu9FWbcsqBt3XjpQB4hJEQemRUWzJr1a98GQTMdsTJjqQayT4N2kl9xx14oA4Hyveo3Qj6V3N74VEaEo7bv4RjvXLX1jJaShHHU8GgDL/AJUh71ZeLHOKiZOOlAERpOKcQQaQ9aAE6Gj+WaO9Hp/hQA2iiigApKWjmgBD1ooNFABRRRQAUUUUAFA60Uo/SgA7cU0npTjSUAJ60GijtQAv4N+dFGD60UAfpHLa8seARgjB6+5rG1OxDxhXUDg59T711RhIO7aQc4xnng46d6q3EKMi4A3dM96APDfGPhuK8hmimUOrA9T6/wBa+bfFOiy6Jqj20nKH5o29V9PqK+3td0pJE3MqEA7sivEPi34RN/p++JP38TFo2A60AfOx60A457g5p8qFHKsMEHBHoR2qOgDpvDXjDUtDlTbK89sDzGx5Hupr3Lw940ttQtUlinRg4BIPBB/xr5nzVmzvZrSTzIJGRh6GgD7Bs9dtt65fnI2gHp9asy69bxgIlwpbJ6HjH+e1fI0niXVGQKt3JHgfwnFNt/EOpwyq/wBrkfBBw5yDQB9U3Op/aCVUgknIUHGPp9Ky55EllHygbuuOAfWvI9C8fnCrOxQgdGPAPsa7HTfE0F2uZGXdnqDxjt/hQB0nlDc25A49xgj8KswwRu+3b1BAz7VFY3UdxJ+7ZGI5x7mtiK3ZFJOD/skUAZj2ke04TLdTWZdWSGQZPJ+Zc9eO4roZ9qxgsdrDgHPeqk8YIQyfiOhoA5O70vcSFyep+pri9e0EXPzBgCDlcDr/AJzXp94pSMlyDnuPSsC8hRwwKLgEmgDyG+0WVUJjwdvUelY8tpNHy6ECvS9SgUg4HHIrl9Xt5ZkIRGwPTt+FAHKmMbcHrULx4/8Ar1auLeSNsOGH4U2OIyfJ3xQBRIpD14qZ0KuQeoprIeuOKAIscUlOIpDQAlHaj+VFACGil70lABRRRQAlLRRQAlOA5pKB1oAXtSUppKAEoP1pRSdqAFwfWil/75/OigD9P2Tk/mKrzRsQcqduOgP+eau45IOOtMZAck9+hPX8aAOfvrfduO0ksCcDnBrivEGntLbyB43weM9CCfQ969FulyuAQHOD06/jXOanbnaxDbGHR/QeooA+Ofix4bbSNbe6hRhb3B+bHRXx/WuCNfTnxV0dL3T7lJB2yuemfWvmq9t2t5nSQYIPNAFUmlBpDSdzQA7NGaSkoAcCRjFaek6i9tKoDEAn1rKFKDjp1oA9s8PeIYIJVjWRWkAAJzXpukajHc2oAwHOM88fWvlTT9Qe1lDckA5POK9c8JeLLJrZFWbEi9Ubhun+eaAPV5xvyEO1j0zz+PvUIi3HAVsisix1y3nhBSZSwGQB1/8Ar1rfaQwDqQTxn5s5Pv8A4UAUru1Z2DBccZI9qwZrDaSNjseRnI6iuryxjITBXbtOD1/z0pssMThgwU5G5SBnjPegDjZrONkYOmCM8jp161m3VhCpdcYJ612M1um1yQB8uCc4/Sue1KMeXtUggk5GOtAHEappwk35VdqggY5wK5CWzkhuyqqXXJwema9NNi9wgbdujbgHGR9OKqXGiKD8wyAev+f/ANdAHldyA0xyNpzzV6HT3kt0IwSwzWzqnh5vtBKKw55H+f51Ys7GazQAICMYwen0NAHF3do8Wcgg5qmR2rs9RhjnDhkO4DOSD/nFc9fae0HzgHYehoAy8UlT+Q7ZwOKjdSvB4oAZSDpS0nrQAUUUUAFFFFABQKKKAFPSm0tJQAtJ+VFLQAmfeinf56iigD9Rx1IGRj2prqG5OeP0p+BxwODn8aQKFzgAZOce9AFK6XdtAwcDB/oc9qw78GMFhyDyFI4H0/z3ropVJQjaDnpj/PNc3q0qrHuZTkdz/hQB5h49gDQTqAAHXHTOfY182eN9PFvKHHXcV6dMV9L+JW+072BBUZwF7V4f8Q7NUsZmwDg5GO1AHk5pvrTnGDzimfSgBaTr0oooAPwo/rSGigB2TSo7IQVJBHQjqKZRQBq2us30EivHdShh6tkV2Gj/ABGu7QIt3GZQvIdMZz6kV51ml3HuaAPc9N+I9tO0QSQg9MEYIz14rfi8TQzoQrDPHU8HH+f/ANdfOMUgVwW6A9q7LT9VsEtionPmkc7h+lAHsj3huFBQ7yRkbcd6YLISkNPkJ1A681xula1aW9sjrKJCOQGPf0rrNM1yC4iYK209+/8AkUAWbmzXIWNfmxyR6djis+eyIRGzuOMdOo960lvbeQoiShWxlSMkZ9vappIfMgDk8c5AoA5mS1XOMKH5BAOPwpfsMbqP3aAZ6Y46VsPZSSS5VlI6de3rz/OrItcKSG3qc43DH0/GgDh7/SYlLYTJPGAv+f8APrXPX2kS3J2xp7DjivTWsyFYld2eoHGPfFUpbSQBmKghjjjpQB5idCa2UmVBtIJ7/wBa46/BM78YGeK9X1O0ub+6aNMCI8exrgvEumfYcDHJz0FAHNHrSU4000ABpO5pc96PXmgBKKO1FABRRRQAUn4cUtJQAtHUUlFAC/lRScepooA/UrrSEgYz+FI5/nUMjnaGBO3JGO57Y/OgCC8mICgfeB9elclq7F9+47dp5xztJ710E7KxZmYggYIPODXP6hGZO8i4+UHPT1x7UAcTrJQLIAOpxuA715P45s2mgdiBjnGBXseqW4VW3D8+T7j61534tRRC0bKOB6cDI/lQB8430RimKnqKrE9a1/EoC6pMF6cGsg+lACUGikzQAfSjuKKKACkJ5oz1pKAHdvajNNzRQA4GnbsdKjyaD9aALMVw8R+U4710Wk+KJbZCskYfjgg4rlM880oNAHe2/jGVJEcgBOMgdV9xXp2heKILmGN12sCMepPHNfPSOgGDnPrWpo2sPpk2+Bjg8MpPGKAPoKS9VeCRgcqKs2n78bQxwe/c/X2rybR/EU11LvkIaLPC4r1PR9Ys1gjXzIzNgHbuHJ7n+VAGsLRdpkbd03AnsehqrcRJKrEYzyGB42/Sr6XjO4KDeCfunp9aTyMgsFwRn8qAOee0RIiEUcdcjFcV4o0Y3pwqN8+Tgf55r1K4t4Fj2u+47eAv6ZNcxq92qMUUIMdT3H+cUAeRSeD3TLSOR1xhe/8ASudvdO+zuymVTjjivQNf1ZmJXceR/COD7muUuLczRvLKpSIDIJHJPpmgDmWG1sdcdKbxUs+BKcYxUfrQAlFHT8KKAD8KKKKAE7UD1paSgAoNFFABxRSUUAfqQ+FUk9uajkTIIz17Dt3qVzgE84FQOTu6BQSOSR0oAqTKGXoQg64ABrCvejY6dfb6etbV8sbp+8VWVSGAI6EdCPcVz+qy7Q285zxQByeruAG4Krt24b868u8ZXHlW8mWYseQOmDj/AAr0TX7oKjbsEDkBufxrwz4mawyWzIjjL/KF3dv8igDy7V5vPv5pOxY1QNPc5NMNAB/Kg0H3pKAD6UnpnilI9qae1AAQKKKT8KACj+VJzQTmgBR1xRRzQOnPSgBf5/Sk6+tJmlz7UALS554pPSjOD/jQBo2N+1vFIikjJByK09J12S0uEdFDuDwWPNc4DU0LHcAvU9KAPojw54qt7u1TzwqNtG7HeulS+huB+6fnOCBXhmn3Fnp8avcXqPKV+bYwbH0xVq38ZwwzMVeQdeo4NAHsd/va2dkWQOQevI+leY6jo2q3d27vI6qX3Ap9a1rHxsLoIjPEwI5J4/yavprkU0X+j7TKDtI9KAOU1i0soYli3g3AB3DoT715xq2oPcOY0JESnhR612+qaTqN7rIuVikCNjnB+n61jat4YIm/cv8AvWPKNwM+xoA4w8nNHvXT/wDCKXcal5zEiDpznNZF/BHEdkfO3qfU0AZxooNFABSClooAKSlpKAAdDR2o9aO1ACUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small bowel follow through examination demonstrates a smooth, well-circumscribed mass arising from the wall of the terminal ileum. The appearance is consistent with a benign mesenchymal tumor, such as a lipoma or a carcinoid tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_48_21263=[""].join("\n");
var outline_f20_48_21263=null;
